Waters Annual Report
Waters The Science What Possible ACQUITY Alliance Empower QDa UPLC and
Xevo are registered trademarks Waters Corporation ACQUITY Arc and Discovery
Series are trademarks Waters Corporation All other trademarks are the property
their respective owners
Waters Corporation Printed the March RRD
Waters Corporation
Maple Street
Milford
waters
Directors
Executive Officers
Douglas Berthiaume
Chairman the Board
Waters Corporation
Christopher Connell
President and Chief
Executive Officer
Christopher Connell
President and
Chief Executive Officer
Waters Corporation
Mark Beaudouin
Senior Vice President
General Counsel and Secretary
Joshua Bekenstein
Managing Director
Bain Capital LLC
Michael Berendt
Life Sciences Industry Consultant
and Investor
Edward Conard
Independent Director and Investor
Laurie Glimcher
President and CEO
Dana Farber Cancer Institute
Principal Investigator and Director
Dana Farber Harvard Cancer Center
Richard and Susan Smith Professor
Medicine Harvard Medical School
Christopher Kuebler
Retired Chairman and Chief
Executive Officer Covance Inc
William Miller
Independent Director and Investor
JoAnn Reed
Health Care Services Consultant
Thomas Salice
Managing Member
SFW Capital Partners LLC
Sherry Buck
Senior Vice President and
Chief Financial Officer
Eugene Cassis
Senior Vice President
Michael Harrington
Senior Vice President
Global Markets
Terrence Kelly
Senior Vice President and President
Instruments
Rohit Khanna
Senior Vice President
Applied Technology
Ian King
Senior Vice President
Instrument Technology
Elizabeth Rae
Senior Vice President
Global Human Resources
David Terricciano
Senior Vice President
Global Operations
Transfer Agent and Registrar
Shareholder correspondence
should mailed
Computershare
Box
College Station
Overnight correspondence
should mailed
Computershare
Quality Circle Suite
College Station
Shareholder website
computershare
investor
Shareholder online inquiries
computershare
investor Contact
Independent Registered
Public Accounting Firm
PricewaterhouseCoopers LLP
Seaport Boulevard
Boston
Phone
Attorneys
Ropes Gray LLP
Prudential Tower
Boylston Street
Boston
Phone
Stockholders Meeting
Date Tuesday May
Location
Waters Corporation
Maple Street
Milford
Directions Call
Ext
waters directionsMilford
Stocklist Symbol
NYSE WAT
Investor Relations
John Lynch
Vice President Treasurer and
Investor Relations
Phone
john_lynch waters
Form
copy the Company filed
with the Securities and Exchange
Commission available without
charge upon written request
Waters Corporation
Maple Street
Milford
Offices
Corporate Headquarters
Waters Corporation
Maple Street
Milford
Phone
Toll Free
Fax
Email info waters
URL waters
Waters the world leading
specialty measurement
company delivering benefit
through innovations and people
that enable customer success
the life materials and
food sciences
Shareholder Report
Dear Customers Employees
and Shareholders
Waters featuring robust organic
Balanced Performance
Across Markets Products
and Geographies
revenue growth meaningful operating
The strength our performance
leverage and solid double digit
was highlighted balanced
Before detailing our results and
earnings per share growth fact
revenue from our key customer
describing the progress are making
growth all three metrics surpassed
markets Leading the way was our
building Waters for the future
our ten year averages Following are
business the broadly defined
would like recognize the
key financial highlights for
pharmaceutical market category
Thank you for your support throughout
pleased report that
was strong fiscal year with growth
revenue and earnings solidly above
historical averages
women and men with whom have
Two Thousand and Sixteen
was year proud for
where revenues grew
the privilege work Throughout
first full year with Waters traveled
extensively meet with thousands
Sales grew before
constant currency basis
currency translation reduced
Rising regulations increasing global
the growth rate
patient access medications and
the growing molecular complexity
colleagues and the customers
Operating income grew
serve all over the world biggest
Non GAAP earnings per fully
take away from this busy and exciting
diluted share were
year has been the strong sense
per share
values and purpose embodied
newer biologic drugs are all macro
trends driving our pharmaceutical
business Laboratories all kinds
within both pharmaceutical and
Free cash flow million
biotechnology firms well
cash flow for each
contract organizations are investing
for our customers and our company
dollar sales exceeded the
infrastructure and people create
and shows the results
half billion threshold for the
safe and effective medications
produced truly our people that
first time and
robust and compliant manner
Our share repurchase program
The year also saw strong performance
returned million
from Waters industrial category
shareholders
which comprises the materials food
all Waters employees They work
tirelessly every day what right
make the Waters difference
environmental and fine chemical
markets With demand across all
product lines sales into food quality
and safety testing well fine
our Discovery Differential Scanning
Europe also performed well
chemical applications steadily grew
Calorimeter DSC and Discovery
particularly pharmaceutical and
strength throughout For the full
Thermal Gravimetric Analyzer TGA
industrial markets while the
year revenues from Waters industrial
have gone very well and expect
Americas contributed additional
category grew
launch additional Discovery
growth for the corporation over
products
strong performance
From product standpoint
saw strong balanced growth
For the third straight year Waters
instruments chemistries and service
recurring revenues grew
Corporate Strategic Framework
Chromatography systems once again
high single digit rate evidence
focused our operations
performed well with high single digit
the enduring benefit bring
and delivered strong also
growth From our workhorse Alliance
customers This consistent
transitioned our new leadership
HPLC systems our sophisticated
performance indicative strong
structure and embarked
ACQUITY UPLC systems Waters
instrument utilization growth
comprehensive strategic planning
offers our customers the industry
service plans and leading technology
process take fresh look our
broadest and most flexible range
positions for advanced separations
markets products and growth
separations options The ACQUITY Arc
chemistries and method specific
strategies with eye towards
chromatography system led our growth
reagent kits Our informatics
enhancing long term value creation
offering customers versatile liquid
products headlined Empower
This process involved hundreds
chromatography system able support
Chromatography Data Systems
employees equally many
validated assays regulated testing
continue differentiate Waters
customers and comprehensive
applications while offering compatibility
regulated workflows More
primary and secondary research
with advanced UPLC methods
pharmaceutical customers use
efforts The outcome these efforts
Empower than any other data system
new corporate framework that
based its ability support the
outlines our values vision strategies
most demanding data integrity
and execution priorities
Also performing well was the
ACQUITY QDa intuitively designed
detector providing molecular mass
standards they face
measurement chromatography
Our aspiration best articulated our
workflows without the cost larger
Geographically Asia once again
vision statement which grounded
footprint and complexity traditional
led Waters global expansion with
our corporate values highlights
mass spectrometry With thousands
mid teens revenue growth
our global scope emphasizes our
installations the few years has
Our operation China delivered
dedication both innovation and
been the market the ACQUITY QDa
twenty percent growth while
customers and identifies the primary
rapidly expanding the adoption
our India business produced mid
markets serve
mass spectrometry the large liquid
teen revenue growth constant
chromatography user base During the
currency basis Strong demand
year launched the Xevo
from the pharmaceutical industry
Waters the world leading
our highest performance tandem
both China and India was key
specialty measurement company
quadrupole mass spectrometer ever
driver the region particular our
designed Early returns are very
customers these rapidly developing
encouraging particularly applied
markets are striving meet rising
customer success the life
markets such food safety and
domestic and international regulatory
materials and food sciences
regulated bio analysis
requirements which call for increased
analytical rigor and the need fortify
our thermal analysis business
launched the Discovery Series line
thermal analyzers completely
new generation this important
category Shipments and installations
the integrity archived data Our
validated instrumentation separations
chemistries and software systems
have positioned well meet these
mission critical customer needs
delivering benefit through
innovations and people that enable
earn the distinction being
recognized the world leading
specialty measurement company
Waters competes the basis focus
innovation and quality Central
our corporate strategy our choice
pursuing these strategies believe
would like close thanking our
very selective about where
that Waters can continue deliver
key stakeholders First and foremost
compete Waters has always benefitted
industry leading growth earnings
thank all our customers for
from serving the most structurally
leverage from ongoing operating
their belief and trust Waters
attractive market segments and
improvement and top tier returns
pledge continuously improve
focusing the most sophisticated
invested capital for our shareholders
your experience every day thank our
measurement technologies for the
always will prioritize the
dedicated talented and passionate
most exacting customers Our analysis
judicious use shareholder capital
employees who deliver benefit
reinforced our choice compete
and sustain our performance oriented
countless ways You are our most
about the billion global
corporate culture
important asset and truly make the
analytical instruments market
and concluded that our highest
Guided Strong Enduring Values
Waters difference Our shareholders
deserve our very best operating results
priority markets pharmaceuticals
Our new strategic framework clear
for their precious investment capital
materials science and food safety
compelling and energizing for our
time and understanding Thank you
offer increasingly attractive growth
management team and employees
for your confidence Finally owe
prospects due rising standards for
builds our historic success
debt gratitude the communities
measurement rigor and end product
company and reinforces many the
which live and work take pride
quality result expect
key business drivers that have defined
being responsible citizens and strive
prioritize continued market focus and
Waters over time while setting the
create shared value everywhere
investment these areas also see
stage for bigger vision and larger
business
potential our more focused positions
value creation opportunities
medical research environmental
are our best and most
However while Waters will
sustainable when serve the
continuously evolve and reinvent itself
interests all our key stakeholders
Robust organic innovation the
compete the changing global
customers employees shareholders
foundation our growth strategy
marketplace our team also recognizes
and our communities Our
the world leader specialty
what should not change the heart
performance demonstrated success
measurement seek sustain
Waters strong set values
this regard and are intent
innovation leadership our core
given our founder Jim Waters
continue this value creation
technologies including liquid
and meticulously built upon every
and beyond
chromatography and related
generation management These
consumables mass spectrometry
values are deeply embedded the
thermal analysis rheology and the
company unique culture and are
sophisticated informatics packages
key driver our strong performance
that drive all our instruments
and keen employee engagement Our
Furthermore within our areas
bedrock values boil down our simple
focus intend lead the market
but profound calling deliver benefit
complete offerings that incorporate
all for customers employees
instruments software consumables
shareholders and the community
analysis and clinical diagnostics
and service deliver truly intelligent
systems our customers
this will able expand the
applications for our technology
world seeking increase the standard
measurement across the life
materials and food sciences
The strongest and most sustainable
companies are firmly guided
enduring values and Waters
exception deliver benefit more
ways and more places than
ever before and are inspired this
timeless core philosophy that has been
part Waters from its original designs
Sincerely
Christopher Connell
President and Chief Executive Off icer
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington
Form
ANNUAL REPORT PURSUANT SECTION
THE SECURITIES EXCHANGE ACT
For the fiscal year ended December
TRANSITION REPORT PURSUANT SECTION
THE SECURITIES EXCHANGE ACT
Commission File Number
Waters Corporation
Exact name registrant specified its charter
Delaware
State other jurisdiction
incorporation organization
Employer
Identification
Maple Street
Milford Massachusetts
Address including zip code principal executive offices
Registrant telephone number including area code
Securities registered pursuant Section the Act
Common Stock par value per share
New York Stock Exchange Inc
Securities registered pursuant Section the Act
None
Indicate check mark the registrant well known seasoned issuer defined Rule the Securities
Act Yes
Indicate check mark the registrant not required file reports pursuant Section Section the
Act Yes
Indicate check mark whether the registrant has filed all reports required filed Section the
Securities Exchange Act during the preceding months for such shorter period that the registrant was required file
such reports and has been subject such filing requirements for the past days Yes
Indicate check mark whether the registrant has submitted electronically and posted its corporate website any every
Interactive Data File required submitted and posted pursuant Rule Regulation this chapter during
the preceding months for such shorter period that the registrant was required submit and post such
files Yes
Indicate check mark disclosure delinquent filers pursuant Item Regulation this chapter
not contained herein and will not contained the best registrant knowledge definitive proxy information statements
incorporated reference Part III this Form any amendment this Form
Indicate check mark whether the registrant large accelerated filer accelerated filer non accelerated filer smaller
reporting company See the definition large accelerated filer accelerated filer and smaller reporting company
Rule the Exchange Act Check one
Large accelerated filer
Accelerated filer
Non accelerated filer
Smaller reporting company
not check smaller reporting company
Indicate check mark whether the registrant shell company defined Rule the Act Yes
State the aggregate market value the registrant common stock held non affiliates the registrant July
Indicate the number shares outstanding the registrant common stock February
DOCUMENTS INCORPORATED REFERENCE
Portions the registrant definitive proxy statement that will filed for the Annual Meeting Stockholders are
incorporated reference Part III
WATERS CORPORATION AND SUBSIDIARIES
ANNUAL REPORT FORM
INDEX
Item
Page
PART
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Executive Officers the Registrant
PART
Market for Registrant Common Equity Related Stockholder Matters and Issuer Purchases
Equity Securities
Selected Financial Data
Management Discussion and Analysis Financial Condition and Results Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes and Disagreements with Accountants Accounting and Financial Disclosure
Controls and Procedures
Other Information
PART III
Directors Executive Officers and Corporate Governance
Executive Compensation
Security Ownership Certain Beneficial Owners and Management and Related Stockholder
Matters
Certain Relationships and Related Transactions and Director Independence
Principal Accountant Fees and Services
PART
Exhibits and Financial Statement Schedules
Form Summary
Signatures
PART
Item Business
General
Waters Corporation the Company analytical instrument manufacturer that primarily designs
manufactures sells and services high performance liquid chromatography HPLC ultra performance liquid
chromatography UPLC and together with HPLC referred LC and mass spectrometry MS
technology systems and support products including chromatography columns other consumable products and
comprehensive post warranty service plans These systems are complementary products that are frequently
employed together MS and sold integrated instrument systems using common software platform
addition the Company designs manufactures sells and services thermal analysis rheometry and calorimetry
instruments through its TA product line The Company also developer and supplier software based
products that interface with the Company instruments well other suppliers instruments and are typically
purchased customers part the instrument system
The Company products are used life science pharmaceutical biochemical industrial nutritional
safety environmental academic and governmental customers working research and development quality
assurance and other laboratory applications The Company and instruments are utilized this
broad range industries detect identify monitor and measure the chemical physical and biological
composition materials and purify full range compounds These instruments are used drug discovery
and development including clinical trial testing the analysis proteins disease processes known
proteomics nutritional safety analysis and environmental testing instruments combine liquid phase
sample introduction and separation system with mass spectrometric compound identification and quantification
The Company thermal analysis rheometry and calorimetry instruments are used predicting the suitability
and stability fine chemicals pharmaceuticals water polymers metals and viscous liquids for various
industrial consumer goods and healthcare products well for life science research
Waters Corporation organized Delaware corporation holding company that owns all the
outstanding common stock Waters Technologies Corporation its operating subsidiary Waters Corporation
became publicly traded company with its initial public offering IPO November Since the IPO the
Company has added two significant and complementary technologies its range products with the
acquisitions Instruments May and Micromass Limited September
Business Segments
The Company business activities for which discrete financial information available are regularly reviewed
and evaluated the chief operating decision maker result this evaluation the Company determined that
has two operating segments Waters and The Company operates the analytical instruments industry
designing manufacturing distributing and servicing instrument systems columns and other chemistry
consumables that can integrated and used along with other analytical instruments The Company two
operating segments have similar economic characteristics product processes products and services types and
classes customers methods distribution and regulatory environments Because these similarities the two
operating segments have been aggregated into one reporting segment for financial statement purposes
Information concerning revenues and long lived assets attributable each the Company products
services and geographic areas set forth Note the Notes the Consolidated Financial Statements which
incorporated herein reference
Waters Products and Markets
High Performance and Ultra Performance Liquid Chromatography
HPLC standard technique used identify and analyze the constituent components variety chemicals
and other materials The Company believes that HPLC performance capabilities enable separate identify
and quantify approximately all known chemicals and materials result HPLC used analyze
substances wide variety industries for research and development purposes quality control and process
engineering applications
The most significant end use markets for HPLC are those served the pharmaceutical and life science
industries these markets HPLC used extensively understand diseases identify new drugs develop
manufacturing methods and assure the potency and purity new pharmaceuticals HPLC also used
variety other applications such analyses foods and beverages for nutritional labeling and compliance
with safety regulations and the testing water and air purity within the environmental testing industry well
applications other industries such chemical and consumer products HPLC also used universities
research institutions and governmental agencies such the United States Food and Drug Administration
FDA and the United States Environmental Protection Agency EPA and their foreign counterparts that
mandate testing requiring HPLC based methodologies
Waters introduced novel technology that the Company describes ultra performance liquid
chromatography that utilizes packing material with small uniform diameter particles and specialized
instrument the ACQUITY UPLC accommodate the increased pressure and narrow chromatographic bands
that are generated these small particles using the ACQUITY UPLC researchers and analysts are able
achieve more comprehensive chemical separations and faster analysis times comparison with many analyses
performed HPLC addition using the ACQUITY UPLC researchers have the potential extend the
range applications beyond that HPLC enabling them uncover more levels scientific information
While offering significant performance advantages the ACQUITY UPLC also compatible with the Company
software products and the general operating protocols HPLC For these reasons the Company customers and
field sales and support organizations are well positioned utilize this new technology and instrument
the Company introduced UltraPerformance Convergence Chromatography with the release the
ACQUITY system This new technology marries the unrealized potential supercritical fluid
chromatography SFC with the proven UPLC technology using carbon dioxide the primary mobile phase
varying mobile phase strength pressure temperature and stationary phase with user can separate
detect and quantify structural analogs isomers enantiomeric and diasteriomeric mixtures all compounds
samples that challenge today laboratories the Company introduced the ACQUITY UPLC Class
instrument system This system delivers the sensitivity quantify and identify vanishingly small concentrations
key molecules particularly when used with advanced mass spectrometric characterization The innovations
incorporated into the ACQUITY UPLC Class system are led its internal low volume design and newly
redesigned fluidics that minimize dispersive and adsorptive losses during chromatographic separation
the Company introduced the ACQUITY Arc System and its enabling Arc Multi flow pathTM technology which
bridges the gap between HPLC and UPLC emulating variety HPLC systems without altering the
method gradient table and enabling improved chromatographic performance methods leveraging
micron particle column technologies
Waters manufactures instruments that are offered configurations that allow for varying degrees
automation from component configured systems for academic teaching and research applications fully
automated systems for regulated testing and that have variety detection technologies from ultra violet
UV absorbance optimized for certain analyses The Company also manufactures tailored systems
for the analysis biologics well detector utilizing evaporative light scattering technology expand
the usage compounds that are not amenable absorbance detection
The primary consumable products for are chromatography columns These columns are packed with
separation media used the testing process and are typically replaced regular intervals The
chromatography column contains one several types packing material typically stationary phase particles
made from silica polymeric resins the sample permeates through the column separated into its
constituent components
Waters HPLC columns can used Waters branded and competitors systems The Company
believes that one few suppliers the world that processes silica and polymeric resins packs columns
and distributes its own products doing the Company believes can better ensure product consistency
key attribute for its customers quality control laboratories and can react quickly new customer
requirements The Company believes that its ACQUITY UPLC lines columns are used primarily its
ACQUITY UPLC instrument systems and furthermore that its ACQUITY UPLC instruments primarily use
ACQUITY UPLC columns the Company expanded its CORTECS family with new line
micron silica based solid core particle columns for usage UPLC well HPLC systems addition the
Company introduced size exclusion chromatography columns for the characterization proteins and ACQUITY
columns for chiral and achiral separations the Company introduced the Oasis PRiME HLB
cartridges which process samples faster and deliver samples that are cleaner with fewer
matrix effects than samples prepared using other extraction techniques addition the ACQUITY
UPLC Glycoprotein BEH Amide columns were introduced help biopharmaceutical companies
better understand where glycan groups bonded sugars are located within the therapeutic proteins they are
developing and manufacturing the Company continued expand its column chemistry capabilities
through the introduction CORTECS CORTECS Phenyl CORTECS and CORTECS Shield
addition the Company expanded its TorusTM SFC column line through the introduction four new
preparative SFC columns which are typically larger diameter columns designed for purification laboratories
investigating drug compounds natural products synthetic chemicals
The Company chemistry consumable products also include environmental and nutritional safety testing
products including Certified Reference Materials CRMs and Proficiency Testing products Laboratories
around the world and across multiple industries use these products for quality control and proficiency testing and
also purchase product support services required help with their federal and state mandated accreditation
requirements with quality control over critical pharmaceutical analysis For example the Company provides
tests identify and quantify mycotoxins fungal biological contaminants various agricultural commodities
These test kits provide reliable quantitative detection particular mycotoxins through the choice fluorimetry
HPLC the Company introduced the Afla AQUA test strips for detecting aflatoxins
grain and received USDA GIPSA certification for its Afla lateral flow strip tests for the quantitative analysis
total aflatoxins corn the Company announced single extraction method for the detection
aflatoxins and fumonisins corn and grain using the Afla AQUA and Fumo AQUA
Mass Spectrometry and Liquid Chromatography Mass Spectrometry
powerful analytical technology that used identify unknown compounds quantify known materials
and elucidate the structural and chemical properties molecules measuring the masses molecules that
have been converted into ions
The Company believes technology and market leader the development manufacture sale and
distribution instruments These instruments are typically integrated and used along with other
complementary analytical instruments and systems such chemical electrophoresis chemical
electrophoresis chromatography and gas chromatography wide variety instrumental designs fall within the
overall category instrumentation including devices that incorporate quadrupole ion trap time flight
Tof magnetic sector and ion mobility technologies Furthermore these technologies are often used tandem
maximize the speed and efficacy certain experiments
Currently the Company offers wide range instrument systems utilizing various combinations
quadrupole Tof and ion mobility designs These instrument systems are used drug discovery and
development well for environmental clinical and nutritional safety testing The overwhelming majority
mass spectrometers sold the Company are designed utilize system and liquid compatible interface
such electrospray ionization source the sample introduction device These products supply diverse
market with strong emphasis the life science pharmaceutical biomedical clinical food and beverage and
environmental market segments worldwide
increasingly important detection technology for The Company smaller sized mass
spectrometers such the single quadrupole detector SQD and the tandem quadrupole detector TQD are
often referred detectors and are typically sold part system system upgrade
Larger quadrupole systems such the Xevo and Xevo instruments are used primarily for
experiments performed for late stage drug development including clinical trial testing Quadrupole time flight
TofTM instruments such the Company SYNAPT are often used analyze the role proteins
disease processes application sometimes referred proteomics the Company introduced the
ionKey MSTM system Xevo and Xevo micro The ionKey system physically integrates
UPLC separation into the mass spectrometer producing significant improvement sensitivity with reduced
solvent and sample sizes The Xevo mass spectrometer combines the new Collision Cell with the
signature technologies Tof MRM StepWaveTM and QuanTofTM The Xevo micro more compact
research grade instrument designed acquire sensitive robust and dependable data accelerated rates
acquisition the Company introduced the GlycoWorks RapiFluor MS Glycan Kit which enables
fast glycosylation and labeling reduces sample preparation time and allows mass detection for
characterization and development with enhanced sensitivity addition the Company introduced the Vion IMS
TofTM Mass Spectrometer which bench top tandem mass spectrometer featuring ion mobility and
Rapid Evaporative Ionization Mass Spectrometry REIMSTM Research System with iKnifeTM sampling
combine direct from sample ionization with high performance time flight mass spectrometry the
Company introduced the Xevo mass spectrometry system enabled the newly designed StepWaveTM
ion guide which features unique combination ion optics detection and ionization technologies resulting
levels sensitivity not previously seen The Company also introduced SONAR which new data
acquisition technology for use with the Xevo that allows for the quantification and identification lipids
metabolites and proteins complex samples more efficient manner
July the Company acquired the net assets Medimass Research Development and Service Kft
Medimass developer mass spectrometry related technologies with the potential used for variety
applications for million cash addition the Company potentially has pay additional contingent
consideration which had estimated fair value million the closing date The net assets acquired
consist primarily the REIMS technology including patent applications software databases and REIMS
expertise REIMS ambient pressure surface ionization technique that when used with mass spectrometry
can characterize the molecular topography complex surfaces such cellular membranes
November the Company acquired all the outstanding stock MPE Orbur Group Limited and its
sole operating subsidiary Midland Precision Equipment Company Ltd MPE manufacturer
instrumentation components for million net cash acquired MPE highly skilled manufacturer and
former Waters supplier that produces critical components that support the Company instrument systems
and are typically embodied within analytical system tailored for either dedicated class
analyses general purpose analytical device increasing percentage the Company customers are
purchasing and components simultaneously and has become common for and instrumentation
used within the same laboratory and operated the same user The descriptions and above
reflect the historical segmentation these analytical technologies and the historical categorization their
respective practitioners Increasingly today instrument market this segmentation and categorization
becoming obsolete high percentage instruments used the laboratory embody both and
technologies part single device response this development and further promote the high
utilization these hybrid instruments the Company has organized its Waters operating segment develop
manufacture sell and service integrated systems
Based upon reports from independent marketing research firms and publicly disclosed sales figures from
competitors the Company believes that one the world largest manufacturers and distributors and
instrument systems chromatography columns and other consumables and related services The Company
also believes that has the leading combined and market share the United States Europe and Asia
excluding Japan and believes may have market share position Japan that ranks second established
domestic supplier
The Company has been developer and supplier software based products that interface with the
Company instruments well other suppliers instruments The Company newest software platform
UNIFI scientific information system that the culmination multi year effort substantially bring all
Waters preexisting distinct software systems under one operating system UNIFI joins Waters suite
informatics products Empower Chromatography Data Software MassLynx Mass Spectrometry Software
and NuGenesis Scientific Data Management System each which used support innovations within
world leading institutions UNIFI the industry first comprehensive software that seamlessly integrates UPLC
chromatography mass spectrometry and informatics data workflows the Company introduced three
new UNIFI based instrument systems and now offers total eight UNIFI based solutions the
Company introduction the Vion IMS Tof Mass Spectrometer marks the first Waters mass spectrometer
fully supported UNIFI the Company announced two reference libraries available within UNIFI
the Metabolic Profiling CCS Library and the RapiFluor MS Glycan Scientific Library The Company also
introduced Symphony Data Pipeline software which client server application that automates the
movement and transformation large amounts data speed analytical workflows and liberate
scientists from mundane yet necessary tasks associated with managing data files
Waters Service
Services provided Waters enable customers maximize technology productivity support customer
compliance activities and provide transparency into enterprise resource management efficiencies The customer
benefits from improved budget control data driven technology adoption and accelerated workflow site
global perspective The Company considers its service offerings highly differentiated from our
competition evidenced consistent increase annual service revenues The Company principal
competitors the service market include PerkinElmer Inc Agilent Technologies Inc Thermo Fisher
Scientific Inc and General Electric Company These competitors can provide certain services Waters
instruments varying degrees and always present competitive risk
The servicing and support instruments software and accessories important source revenue and
represents over sales for Waters These revenues are derived primarily through the sale support plans
demand services spare parts customer performance validation services and customer training Support plans
typically involve scheduled instrument maintenance and agreement promptly repair non functioning
instrument return for fee described contract that priced according the configuration the
instrument
Products and Markets
Thermal Analysis Rheometry and Calorimetry
Thermal analysis measures the physical thermodynamic characteristics materials function
temperature Changes temperature affect several characteristics materials such their heat flow
characteristics physical state weight dimension and mechanical and electrical properties which may
measured one more thermal analysis techniques including calorimetry Consequently thermal analysis
techniques are widely used the development production and characterization materials various industries
such plastics chemicals automobiles pharmaceuticals and electronics
Rheometry instruments often complement thermal analyzers characterizing materials Rheometry
characterizes the flow properties materials and measures their viscosity elasticity and deformation under
different types loading other conditions The information obtained under such conditions provides insight
into material behavior during processing packaging transport usage and storage
Thermal analysis rheometry and calorimetry instruments are heavily used material testing laboratories
and many cases provide information useful predicting the suitability and stability industrial polymers
fine chemicals pharmaceuticals water metals and viscous liquids various industrial consumer goods and
healthcare products well for life science research with systems offered Waters range
instrument configurations available with increasing levels sample handling and information processing
automation addition systems and accompanying software packages can tailored for specific applications
introduced the TAM and TAM which extend the operating temperature range
with long term temperature stability for measuring processes also introduced the Affinity
ITC and ITC Auto which are designed for the most challenging life science laboratory environments that require
high sensitivity high productivity and the most advanced isothermal titration calorimetry
introduced new line differential scanning calorimeters and thermogravimetric analyzers These new
Discovery DSC systems feature enhanced sensing technologies resulting unprecedented performance
baseline flatness sensitivity resolution and reproducibility addition introduced the ACS Air Chiller
System ElectroForce test instrument and DuraPulseTM Stent Graft test instrument
January the Company acquired ULSP ULSP manufacturer instrumentation
components that enable ultra low temperature generation for million cash ULSP core business the
manufacturing and servicing high quality low temperature coolers for thermal analysis and rheology
applications and these products are important accessories for many core instrument offerings
introduced the new Air Chiller System ACS which equipped with three stage cascading compressor
design enabling testing temperatures low capability that the Company believes competing
systems not possess
May the Company acquired the net assets the ElectroForce business the Bose Corporation
ElectroForce manufacturer testing systems for million cash ElectroForce core business the
manufacturing dynamic mechanical testing systems used characterize medical devices biologic and
engineered materials The ElectroForce test instruments are based unique motor designs that are quiet energyefficient and scalable while delivering precise performance over wide range force and frequency
September the Company acquired all the outstanding stock Rubotherm GmbH
Rubotherm manufacturer gravimetric analysis systems for approximately million cash million
which was paid closing and additional million paid after closing settle certain liabilities Rubotherm
develops and manufactures analytical test instruments for thermogravimetric and sorption measurements that are
used both industrial and academic research laboratories disciplines that include chemistry material science
and engineering The Rubotherm acquisition will help support and further expand product offerings within TA
thermal analysis business
Service
Similar Waters the servicing and support TA instruments important source revenue and
represents more than sales for operates independently from the Waters operating segment
though many its overseas offices are situated Waters facilities achieve operational efficiencies has
dedicated field sales and service operations Service sales are primarily derived from the sale support plans
replacement parts and billed labor fees associated with the repair maintenance and upgrade installed systems
Customers
The Company typically has broad and diversified customer base that includes pharmaceutical accounts other
industrial accounts universities and governmental agencies Purchase the Company instrument systems
often dependent its customers capital spending funding the cases governmental academic and
research institutions which often fluctuate from year year The pharmaceutical segment represents the
Company largest sector and includes multinational pharmaceutical companies generic drug manufacturers
contract research organizations CROs and biotechnology companies The Company other industrial
customers include chemical manufacturers polymer manufacturers food and beverage companies and
environmental testing laboratories The Company also sells universities and governmental agencies
worldwide The Company technical sales and support staff members work closely with its customers
developing and implementing applications that meet their full range analytical requirements During
the Company sales were pharmaceutical accounts other industrial accounts and
governmental agencies and academic institutions
The Company typically experiences increase sales the fourth quarter result purchasing habits
for capital goods many customers who tend exhaust their spending budgets calendar year end The
Company does not rely any single customer for material portion its sales During fiscal years
and single customer accounted for more than the Company net sales
Sales and Service
The Company has one the largest direct sales and service organizations focused exclusively the
technologies offered the Company Across these product technologies using respective specialized sales and
service workforces the Company serves its customer base with sales offices throughout the world
December and approximately and field representatives and
respectively This investment sales and service personnel serves maintain and expand the Company
installed base instruments The Company sales representatives have direct responsibility for account
relationships while service representatives work the field install instruments train customers and minimize
instrument downtime house and field based technical support representatives work directly with customers
providing them assistance with applications and procedures Company products The Company provides
customers with comprehensive information through various corporate and regional internet websites and product
literature and also makes consumable products available through electronic ordering facilities and dedicated
catalog
Manufacturing and Distribution
The Company provides high product quality overseeing each stage the production its instruments
columns and chemical reagents
The Company currently assembles portion its instruments its facility Milford Massachusetts
where performs machining assembly and testing The Milford facility maintains quality management and
environmental management systems accordance with the requirements ISO ISO
and ISO and adheres applicable regulatory requirements including the FDA Quality System
Regulation and the European Vitro Diagnostic Directive The Company outsources manufacturing certain
electronic components such computers monitors and circuit boards outside vendors that meet the
Company quality requirements addition the Company outsources the manufacturing certain
instrument systems and components well established contract manufacturing firms Singapore The
Company Singapore entity ISO certified and manages all Asian outsourced manufacturing well
the distribution all products from Asia The Company may pursue outsourcing opportunities they arise
but believes maintains adequate supply chain and manufacturing capabilities the event disruption
natural disasters
The Company manufactures certain SFC SFE products its facility Sharpsburg Pennsylvania The
Sharpsburg facility aligned with the policies and procedures for product manufacturing and distribution
adhered the Milford Massachusetts facility and under the same structural leadership organization
The Company primarily manufactures and distributes its columns its facilities Taunton
Massachusetts and Wexford Ireland The Taunton facility processes sizes and treats silica and polymeric media
that are packed into columns solid phase extraction cartridges and bulk shipping containers both Taunton and
Wexford The Wexford facility also manufactures and distributes certain data instruments and software
components for the Company and product lines The Company Taunton facility certified
ISO The Wexford facility certified ISO and ISO ISO
VICAM manufactures antibody linked resins and magnetic beads that are packed into columns and kits
Milford Massachusetts and Nixa Missouri The Company manufactures and distributes its Analytical Standards
and Reagents and Environmental Resource Associates ERA product lines its facility Golden Colorado
which certified ISO and accredited ISO IEC ISO IEC and ISO Guide Some
ERA products are also manufactured the Wexford Ireland facility
The Company manufactures and distributes its products its facilities Wilmslow England and
Wexford Ireland Certain components modules the Company instruments are manufactured its
facility Solihull England and long standing outside contractors Each stage this supply chain closely
monitored the Company maintain high quality and performance standards The instruments components
modules are then returned the Company facilities where its engineers perform final assembly calibrations
customer specifications and quality control procedures The Company facilities are certified ISO
and ISO ISO
TA thermal analysis rheometry and calorimetry products are manufactured and distributed the
Company New Castle Delaware Wakefield Massachusetts Eden Prairie Minnesota Lindon Utah Bochum
Germany Huellhorst Germany Wetzlar Germany and Ede Netherlands facilities Similar elements
TA products are manufactured outside contractors and are then returned the Company facilities for final
assembly calibration and quality control The Company New Castle facility certified ISO
standards and the Eden Prairie facility certified both ISO and ISO IEC standards
Raw Materials
The Company purchases variety raw materials primarily consisting high temperature alloy sheet metal
and castings forgings pre plated metals and electrical components from various vendors The materials used
the Company operations are generally available from number sources and sufficient quantities meet
current requirements subject normal lead times
The Company subject rules the Securities and Exchange Commission SEC under the DoddFrank Wall Street Reform and Consumer Protection Act requiring disclosure whether certain materials
tantalum tin gold and tungsten known conflict minerals which may contained the Company
products are mined from the Democratic Republic the Congo and adjoining countries the Company
was not able determine with certainty the country origin some the conflict minerals its
manufactured products However the Company does not have knowledge that any its conflict minerals
originated from the Democratic Republic the Congo adjoining countries The Company the process
evaluating its supply chain and the Company plans file its Form with the SEC May
The results this and future evaluations may impose additional costs and may introduce new risks related the
Company ability verify the origin any conflict minerals contained its products
addition the Company continues monitor environmental health and safety regulations countries
which operates throughout the world particular European Union and China Restrictions the use
certain Hazardous Substances electrical and electronic equipment RoHS and European Union Waste
Electrical and Electronic Equipment directives Further information regarding these regulations available
the Company website waters under the caption About Waters Environmental Health Safety
Research and Development
The Company maintains active research and development program focused the development and
commercialization products that extend complement and update its existing product offering The Company
research and development expenditures for and were million million and
million respectively addition and the Company incurred charges million and
million respectively for acquired process research and development related the licensing certain
intellectual property relating mass spectrometry technologies yet commercialized and for which there
was future alternative use the acquisition date These licensing arrangements are significantly related
new biologically focused applications well other applications and require the Company make
additional future payments million certain milestones are achieved well royalties future
net sales
Nearly all the Company products have been developed the Company main research and
development center located Milford Massachusetts with input and feedback from the Company extensive
field organizations and customers The majority the Company products are developed facilities
England and most the Company current materials characterization products are developed the Company
research and development center New Castle Delaware December and there were
and employees respectively involved the Company research and development efforts The
Company has increased research and development expenses from its continued commitment invest
significantly new product development and existing product enhancements and result acquisitions
Despite the Company active research and development programs there can assurance that the
Company product development and commercialization efforts will successful that the products developed
the Company will accepted the marketplace
Employees
The Company employed approximately and employees December and
respectively with approximately the Company employees located the United States The
Company believes its employee relations are generally good The Company employees are not unionized
affiliated with any internal external labor organizations The Company firmly believes that its future success
largely depends upon its continued ability attract and retain highly skilled employees
Competition
The analytical instrument systems supplies and services market highly competitive The Company encounters
competition from several worldwide suppliers and other companies both domestic and foreign markets for
each its three primary technologies The Company competes its markets primarily the basis product
performance reliability service and lesser extent price Competitors continuously introduce new products
and have instrument businesses that are generally more diversified than the Company business Some
competitors have greater financial resources and broader distribution than the Company
the markets served Waters the Company principal competitors include Agilent Technologies Inc
Shimadzu Corporation Bruker Corporation Danaher Corporation and Thermo Fisher Scientific Inc the
markets served the Company principal competitors include PerkinElmer Inc Mettler Toledo
International Inc NETZSCH Geraetebau GmbH Thermo Fisher Scientific Inc Malvern Instruments Ltd and
Anton Paar GmbH
The market for consumable products including separation columns highly competitive and generally
more fragmented than the analytical instruments market The Company encounters competition the
consumable columns market from chemical companies that produce column sorbents and small specialized
companies that primarily pack purchased sorbents into columns and subsequently package and distribute
columns The Company believes that one the few suppliers that processes silica and polymeric resins
packs columns and distributes its own products The Company competes this market the basis
performance reproducibility reputation and lesser extent price recent years the Company principal
competitors for consumable products have included Danaher Corporation Merck KGaA Darmstadt Germany
Agilent Technologies Inc General Electric Company and Thermo Fisher Scientific Inc The ACQUITY UPLC
instrument designed offer predictable level performance when used with ACQUITY UPLC columns
and the Company believes that the expansion the ACQUITY UPLC instrument base will enhance its
chromatographic column business because the high level synergy between ACQUITY UPLC columns and
the ACQUITY UPLC instruments
Patents Trademarks and Licenses
The Company owns number United States and foreign patents and has patent applications pending the
United States and abroad Certain technology and software has been acquired licensed from third parties
The Company also owns number trademarks The Company patents trademarks and licenses are viewed
valuable assets its operations However the Company believes that one patent group patents
trademark license and itself essential the Company such that its loss would materially affect the
Company business whole
Environmental Matters and Climate Change
The Company subject federal state and local laws regulations and ordinances that govern activities
operations that may have adverse environmental effects such discharges air and water well handling
and disposal practices for solid and hazardous wastes and impose liability for the costs cleaning and
certain damages resulting from sites past spills disposals other releases hazardous substances The
Company believes that currently conducts its operations and has operated its business the past substantial
compliance with applicable environmental laws From time time Company operations have resulted may
result noncompliance with environmental laws liability for cleanup pursuant environmental laws The
Company does not currently anticipate any material adverse effect its operations financial condition
competitive position result its efforts comply with environmental laws
The Company sensitive the growing global debate with respect climate change internal
sustainability working group develops increasingly robust data with respect the Company utilization
carbon producing substances effort continuously reduce the Company carbon footprint the
Company published sustainability report identifying the various actions and behaviors the Company has
adopted concerning its commitment both the environment and the broader topic social responsibility See
Item Risk Factors The effects climate change could harm the Company business for more
information the potential significance climate change legislation See also Note the Notes the
Consolidated Financial Statements for financial information about geographic areas
Available Information
The Company files furnishes all required reports with the SEC The public may read and copy any materials
the Company files furnishes with the SEC the SEC Public Reference Room Street
Washington The public may obtain information the operation the Public Reference Room
calling the SEC SEC
The Company electronic filer and the SEC maintains website that contains reports proxy and
information statements and other information regarding issuers that file electronically with the SEC The address
the SEC electronic filing website http sec gov The Company also makes available free charge
its website its annual report Form quarterly reports Form current reports Form and
any amendments those reports soon reasonably practicable after such material electronically filed with
furnished the SEC The website address for Waters Corporation http waters and SEC filings
can found under the caption Investors
Forward Looking Statements
Certain the statements this Form and the documents incorporated herein may contain forward looking
statements within the meaning Section the Securities Act amended and Section the
Securities Exchange Act amended the Exchange Act with respect future results and events
including any statements regarding among other items anticipated trends growth the Company business
including but not limited the impact foreign currency translation financial results development
products acquired businesses the growth rate sales and research and development expenses the impact
costs associated with developing new technologies and bringing these new technologies market the impact
new product launches and the associated costs such the amortization expense related software platforms
geographic sales mix business development products acquired businesses and the amount contingent
payments the sellers acquired business anticipated expenses including interest expense capitalized
software costs and effective tax rates the impact and outcome the Company various ongoing tax audit
examinations the achievement contractual milestones preserve foreign tax rates the impact and outcome
litigation matters the impact the loss intellectual property protection the impact new accounting
standards and pronouncements the adequacy the Company supply chain and manufacturing capabilities and
facilities the impact regulatory compliance the Company expected cash flow borrowing capacity debt
repayment and refinancing the Company ability fund working capital capital expenditures service debt
repay outstanding lines credit make authorized share repurchases fund potential acquisitions and pay any
adverse litigation tax audit liabilities particularly the future impairment charges the Company
contributions defined benefit plans the Company expectations regarding changes its financial position
compliance with applicable environmental laws and the impact recent acquisitions sales and earnings
Many these statements appear particular under the heading Management Discussion and Analysis
Financial Condition and Results Operations Part Item this Form Statements that are not
statements historical fact may deemed forward looking statements You can identify these forward looking
statements the use the words feels believes anticipates plans expects may will would
intends suggests appears estimates projects should and similar expressions whether the
negative affirmative These statements are subject various risks and uncertainties many which are
outside the control the Company including and without limitation
Foreign exchange rate fluctuations that could adversely affect translation the Company future sales
financial operating results and the condition its non operations especially when currency
weakens against the dollar
Current global economic sovereign and political conditions and uncertainties particularly regarding the
effect the voting exit the European Union well the Chinese government ongoing
tightening restrictions procurement government funded customers the Company ability
access capital and maintain liquidity volatile market conditions customers changes timing and
demand the Company customers and various market sectors particularly they should reduce
capital expenditures are unable obtain funding the cases governmental academic and
research institutions the effect mergers and acquisitions customer demand and the Company
ability sustain and enhance service
Negative industry trends changes the competitive landscape result changes ownership
mergers and continued consolidation among the Company competitors introduction competing
products other companies and loss market share pressures prices from customers resulting
from competition regulatory economic and competitive obstacles new product introductions lack
acceptance new products expansion our business developing markets spending certain
end markets ability obtain alternative sources for components and modules and the possibility that
future sales new products related acquisitions which trigger contingent purchase payments may
exceed the Company expectations
Increased regulatory burdens the Company business evolves especially with respect the FDA and
EPA among others well regulatory environmental and logistical obstacles affecting the distribution
the Company products completion purchase order documentation our customers and ability
customers obtain letters credit other financing alternatives
Risks associated with lawsuits particularly involving claims for infringement patents and other
intellectual property rights
The impact and costs incurred from changes accounting principles and practices the impact and costs
changes statutory contractual tax rates shifts taxable income among jurisdictions with different
effective tax rates and the outcome and costs associated with ongoing and future tax audit
examinations changes respective country legislation affecting the Company effective rates
Certain these and other factors are further described below Item Risk Factors this Form
Actual results events could differ materially from the plans intentions and expectations disclosed the
forward looking statements whether because these factors for other reasons All forward looking
statements speak only the date this annual report Form and are expressly qualified their
entirety the cautionary statements included this report Except required law the Company does not
assume any obligation update any forward looking statements
Item
Risk Factors
The Company subject risks common companies the analytical instrument industry including but not
limited the following
The Company international operations may negatively affected political events wars terrorism and
regulatory changes related either specific country larger region These potential political currency
and economic disruptions well foreign currency exchange rate fluctuations could have material adverse
effect the Company results operations financial condition
Approximately and the Company net sales and respectively were outside the
United States and were primarily denominated foreign currencies addition the Company has considerable
manufacturing operations Ireland and the United Kingdom well significant subcontractors located
Singapore result significant portion the Company sales and operations are subject certain risks
including adverse developments the political regulatory and economic environment particular uncertainty
regarding possible changes foreign and domestic trade policy the effect the voting exit the
European Union well the financial difficulties and debt burden experienced number European
countries the instability and potential impact war terrorism the instability and possible dissolution the
Euro single currency sudden movements country foreign exchange rates due change
country sovereign risk profile foreign exchange regulatory practices tariffs and other trade barriers
difficulties staffing and managing foreign operations and associated adverse operational contractual and tax
consequences
Additionally the dollar value the Company net sales cost sales operating expenses interest
taxes and net income varies with foreign currency exchange rate fluctuations Significant increases decreases
the value the dollar relative certain foreign currencies particularly the Euro Japanese yen and
British pound could have material adverse effect benefit the Company results operations financial
condition
Global economic conditions may decrease demand for the Company products and harm the Company
financial results
The Company global business that may adversely affected changes global economic conditions
These changes global economic conditions both inside and outside the may affect the demand for the
Company products and services This may result decline sales the future increased rate order
cancellations delays increased risk excess obsolete inventories longer sales cycles and potential
difficulty collecting sales proceeds There can assurance regarding demand for the Company products
and services the future
The Company financial results are subject changes customer demand which may decrease for number
reasons many beyond the Company control
The demand for the Company products dependent upon the size the markets for its thermal
analysis rheometry and calorimetry products the timing and level capital spending and expenditures the
Company customers changes governmental regulations particularly affecting drug food and drinking water
testing funding available governmental academic and research institutions general economic conditions and
the rate economic growth the Company major markets and competitive considerations The Company
typically experiences increase sales its fourth quarter result purchasing habits for capital goods
customers that tend exhaust their spending budgets calendar year end There can assurance that the
Company results operations financial condition will not adversely impacted change any the
factors listed above the continuation uncertain global economic conditions
Additionally the analytical instrument market may from time time experience low sales growth
Approximately and the Company net sales and respectively were the worldwide
pharmaceutical and biotechnology industries which may periodically subject unfavorable market
conditions and consolidations Unfavorable industry conditions could have material adverse effect the
Company results operations financial condition
Disruption worldwide financial markets could adversely impact the Company access capital and financial
condition
Financial markets the Europe and Asia have experienced times extreme disruption recent years
including among other things sharp increases the cost new capital credit rating downgrades and bailouts
severely diminished capital availability and severely reduced liquidity money markets Financial and banking
institutions have also experienced disruptions resulting large asset write downs higher costs capital rating
downgrades and reduced desire lend money There can assurance that there will not future
deterioration prolonged disruption financial markets financial institutions Any future deterioration
prolonged disruption financial markets financial institutions which the Company participates may impair
the Company ability access its existing cash utilize its existing syndicated bank credit facility funded
such financial institutions and impair its ability access sources new capital The cost the Company any
new capital raised and interest expense would increase this were occur
Competitors may introduce more effective less expensive products than the Company which could result
decreased sales The competitive landscape may transform result potential changes ownership
mergers and continued consolidations among the Company competitors which could harm the Company
business
The analytical instrument market and particular the portion related the Company HPLC UPLC
thermal analysis rheometry and calorimetry product lines highly competitive and subject rapid changes
technology The Company encounters competition from several international instrument suppliers and other
companies both domestic and foreign markets Some competitors have instrument businesses that are
generally more diversified than the Company business but are typically less focused the Company chosen
markets Over the years some competitors have merged with other competitors for various reasons some
which include increasing product line offerings improving market share and reducing costs There can
assurance that the Company competitors will not introduce more effective and less costly products than those
the Company that the Company will able increase its sales and profitability from new product
introductions There can assurance that the Company sales and marketing forces will compete
successfully against the Company competitors the future
Strategies for organic growth require developing new technologies and bringing these new technologies
market which could negatively impact the Company financial results
The Company the process developing new products with recently acquired technologies The future
development these new products will require significant amount spending over the next few years before
significant robust sales will realized These new products will sold into both the clinical and non clinical
markets and any new products requiring FDA clearance may take longer bring market There can
assurance given the timing these new product launches and the ultimate realization sales and
profitability the future
addition despite testing prior the release and throughout the lifecycle product service the
Company software hardware may contain coding manufacturing errors that could impact their function
performance and security and result other negative consequences The detection and correction any errors
released software hardware can time consuming and costly This could delay the development release
new products services new versions products services create security vulnerabilities the
Company products services and adversely affect market acceptance products services the Company
experiences errors delays releasing its software hardware new versions thereof its sales could
affected and revenues could decline Errors software hardware could expose the Company product
liability performance and warranty claims well harm brand and reputation which could impact future
sales
The Company financial condition and results operations could adversely affected the Company
unable maintain sufficient level cash flow the
The Company had million debt and million cash cash equivalents and investments
December December the Company also had the ability borrow additional
million from its existing committed credit facility All but small portion the Company debt the
There substantial cash requirement the fund operations and capital expenditures service debt
interest obligations finance potential acquisitions and continue authorized stock repurchase programs the
majority the Company cash generated from foreign operations with million the
Company cash held foreign subsidiaries and may subject material tax effects distribution
legal entities The Company financial condition and results operations could adversely impacted the
Company unable maintain sufficient level cash flow the address these requirements through
cash from operations efficient cost effective and timely distribution cash from non
subsidiaries the Company ability access its existing cash and revolving credit facility the ability
expand the Company borrowing capacity and other sources capital obtained acceptable cost
Debt covenants and the Company failure comply with them could negatively impact the Company capital
and financial results
The Company debt subject restrictive debt covenants that limit the Company ability engage certain
activities that could otherwise benefit the Company These debt covenants include restrictions the Company
ability enter into certain contracts agreements that may limit the Company ability make dividend
other payments secure other indebtedness enter into transactions with affiliates and consolidate merge
transfer all substantially all the Company assets The Company also required meet specified financial
ratios under the terms the Company debt agreements The Company ability comply with these financial
restrictions and all other covenants dependent the Company future performance which subject but
not limited prevailing economic conditions and other factors including factors that are beyond the Company
control such foreign exchange rates interest rates changes technology and changes the level
competition
Disruption operations the Company manufacturing facilities could harm the Company financial
condition
The Company manufactures instruments facilities Milford Massachusetts and through subcontractor
Singapore chemistry separation columns its facilities Taunton Massachusetts and Wexford Ireland
products its facilities Wilmslow England Solihull England and Wexford Ireland thermal analysis and
rheometry products its facilities New Castle Delaware and other instruments and consumables various
other locations result the Company acquisitions Any prolonged disruption the operations any
these facilities whether due labor difficulties destruction damage any facility other reasons could
have material adverse effect the Company results operations financial condition
The loss key members management and the risks inherent succession planning could adversely affect the
Company results operations financial condition
The operation the Company requires managerial and operational expertise None the Company key
management employees with the exception the President and Chief Executive Officer and the Senior Vice
President and Chief Financial Officer have employment contract with the Company and there can
assurance that such individuals will remain with the Company for any reason other such key personnel not
continue active management the Company results operations financial condition could
adversely affected
Failure adequately protect intellectual property could have materially adverse effects the Company
results operations financial condition
The Company vigorously protects its intellectual property rights and seeks patent coverage all developments
that regards material and patentable However there can assurance that any patents held the
Company will not challenged invalidated circumvented that the rights granted thereunder will provide
competitive advantages the Company Conversely there could successful claims against the Company
third party patent holders with respect certain Company products that may infringe the intellectual property
rights such third parties The Company patents including those licensed from others expire various
dates the Company unable protect its intellectual property rights could have adverse and material
effect the Company results operations financial condition
The Company business would suffer the Company were unable acquire adequate sources supply
Most the raw materials components and supplies purchased the Company are available from number
different suppliers however number items are purchased from limited single sources supply and
disruption these sources could have minimum temporary adverse effect shipments and the financial
results the Company prolonged inability obtain certain materials components could have adverse
effect the Company financial condition results operations and could result damage its
relationships with its customers and accordingly adversely affect the Company business
The Company sales would deteriorate the Company outside contractors fail provide necessary
components modules
Certain components modules the Company and instruments are manufactured outside
contractors including the manufacturing instrument systems and related components contract
manufacturing firms Singapore Disruptions service these outside contractors could have adverse
effect the supply chain and the financial results the Company prolonged inability obtain these
components modules could have adverse effect the Company financial condition results
operations
The Company financial results are subject unexpected shifts pre tax income between tax jurisdictions
changing application tax law and tax audit examinations
The Company subject rates income tax that range from excess various jurisdictions
which conducts business addition the Company typically generates substantial portion its income
the fourth quarter each fiscal year Geographical shifts income from previous quarters projections caused
factors including but not limited changes volume and product mix and fluctuations foreign currency
translation rates could therefore have potentially significant favorable unfavorable effects the Company
income tax expense effective tax rate and results operations
Governments the jurisdictions which the Company operates implement changes tax laws and
regulations from time time Any changes corporate income tax rates regulations regarding transfer
pricing repatriation dividends capital well changes the interpretation existing tax laws and
regulations the jurisdictions which the Company operates could adversely affect the Company cash flow
and lead increases its overall tax burden which would negatively affect the Company profitability
addition the Company has contractual tax rate Singapore through March based upon the
achievement and continued satisfaction certain operational and financial milestones which the Company
expects continue meet Currently the Company has determined that more likely than not realize the
contractual tax rate Singapore and has not recognized uncertain tax benefit its balance sheet
related the achievement the contractual milestones Singapore the event that appears that the
milestone targets will not met the Company will longer entitled contractual tax rate benefit
income earned Singapore dating back the start date the agreement April which time all tax
benefits previously recorded would reversed and income tax charge equal the statutory tax
income earned during that period would recorded
global business the Company subject tax audit examinations various jurisdictions throughout
the world The Company must manage the cost and disruption responding governmental audits
investigation and proceedings whether not they have merit addition the impact the settlement
pending future tax audit examination could have unfavorable effect the Company income tax expense
effective tax rate and results operations
Disruption cyber attack unforeseen problems with the security maintenance upgrade the Company
information and web based systems could have adverse effect the Company operations and financial
condition
The Company relies its technology infrastructure and that its software and banking partners among other
functions interact with suppliers sell products and services fulfill contract obligations ship products collect
and make electronic wire and check based payments and otherwise conduct business The Company technology
infrastructure may vulnerable damage interruption from but not limited natural disasters power loss
telecommunication failures terrorist attacks computer viruses unauthorized access customer employee
data unauthorized access and funds transfers from Company bank accounts and other attempts harm the
Company systems Any prolonged disruption the Company technology infrastructure any its
facilities could have material adverse effect the Company results operations financial condition
the Company security measures are compromised fail adequately protect its technology infrastructure
research and development efforts manufacturing operations the Company products and services may
perceived vulnerable unreliable the information the Company controls and processes may subject
unauthorized access acquisition modification the Company brand and reputation could damaged the
services that the Company provides its customers could disrupted and customers may stop using the
Company products and services all which could reduce the Company revenue and earnings increase its
expenses and expose the Company legal claims and regulatory actions
The Company the business designing manufacturing selling and servicing analytical instruments life
science pharmaceutical biochemical industrial nutritional safety and environmental academic and
governmental customers working research and development quality assurance and other laboratory
applications and the Company also developer and supplier software based products that support
instrument systems Many the Company customers are highly regulated industries While the Company
has invested time and resources implementing measures designed protect the integrity and security its
technology infrastructure research and development processes manufacturing operations products and services
and the internal and external data managed the Company there risk these measures will defeated
compromised that they are otherwise insufficient protect against existing emerging threats The Company
also has acquired companies products services and technologies over time and may inherit risk when integrating
these acquisitions into the Company addition times the Company faces attempts third parties defeat
its security measures exploit vulnerabilities its systems These risks will increase the Company continues
grow and expand geographically and its systems products and services become increasingly digital and
sensor and web based
The Company could suffer significant damage its brand and reputation security incident resulted
unauthorized access acquisition modification the Company technology infrastructure research and
development processes manufacturing operations its products and services well the internal and external
data managed the Company Such incident could disrupt the Company operations and customers could
lose confidence the Company ability deliver quality and reliable products services This could
negatively impact sales and could increase costs related fixing and addressing these incidents and any
vulnerabilities exposed them well lawsuits regulatory investigations claims legal liability
including contractual liability costs and expenses owed customers and business partners
Compliance failures could harm the Company business
The Company subject regulation various federal state and foreign governments and agencies areas
including among others health and safety import export privacy and data protection the Foreign Corrupt
Practices Act and environmental laws and regulations portion the Company operations are subject
regulation the FDA and similar foreign regulatory agencies These regulations are complex and govern
array product activities including design development labeling manufacturing promotion sales and
distribution Any failure the Company comply with applicable governmental regulations could result
product recalls the imposition fines restrictions the Company ability conduct expand its operations
the cessation all portion its operations
Regulators globally are increasingly imposing greater fines and penalties for privacy and data protection
violations and the European Union has enacted broad data protection regulation with fines based
percentage global revenues Changes laws regulations associated with enhanced protection certain
sensitive types personal information such information related health could greatly increase the cost
compliance and the cost providing the Company products services Any failure perceived failure
the Company comply with laws and regulations privacy data security consumer protection other
policies public perception standards self regulatory requirements legal obligations could result lost
restricted business proceedings actions fines brought against the Company levied governmental entities
others could otherwise adversely affect the business and harm the Company reputation
Some the Company operations are subject domestic and international laws and regulations with
respect the manufacturing handling use sale toxic hazardous substances This requires the Company
devote substantial resources maintain compliance with those applicable laws and regulations the
Company fails comply with such requirements the manufacturing distribution its products could
face civil and criminal penalties and potentially prohibited from distributing selling such products until
they are compliant
Some the Company products are also subject the rules certain industrial standards bodies such
the International Standards Organization The Company must comply with these rules well those other
agencies such the United States Occupational Safety and Health Administration Failure comply with such
rules could result the loss certification and the imposition fines and penalties which could have
material adverse effect the Company operations
publicly traded company the Company subject the rules the Public Company Accounting
Oversight Board the SEC and the New York Stock Exchange addition the Company must comply with the
Sarbanes Oxley rules which require the Company establish and maintain adequate internal control over
financial reporting The Company efforts comply with such laws and regulations are time consuming and
costly however failure comply with such rules could have material adverse effect the Company
financial condition and operations
The Company subject the rules the SEC under the Dodd Frank Wall Street Reform and Consumer
Protection Act requiring disclosure whether certain materials tantalum tin gold and tungsten known
conflict minerals which may contained the Company products are mined from the Democratic Republic
the Congo and adjoining countries the Company was not able determine with certainty the country
origin some the conflict minerals its manufactured products However the Company does not have
knowledge that any its conflict minerals originated from the Democratic Republic the Congo adjoining
countries The Company the process evaluating its supply chain and the Company plans file its
Form with the SEC May The results this and future evaluations may impose additional costs
and may introduce new risks related the Company ability verify the origin any conflict minerals
contained its products
The Company financial condition and results operations could adversely affected changes the
Company retirement plans retirement plan assets
The Company sponsors various retirement plans both inside and outside the Any changes regulations
made governments countries which the Company sponsors retirement plans could adversely impact the
Company cash flows results operations connection with these retirement plans the Company
exposed market risks associated with changes the various capital markets For example changes longterm interest rates affect the discount rate that used measure the Company retirement plan obligations and
related expense addition changes the market value investments held the retirement plans could
materially impact the funded status the retirement plans and affect the related pension expense and level and
timing contributions required under applicable laws
Estimates and assumptions made accounting for the Company results from operations are dependent
future results which involve significant judgments and may imprecise and may differ materially from actual
results
The preparation consolidated financial statements conformity with generally accepted accounting principles
requires the Company make estimates and judgments that affect the reported amounts assets liabilities
revenues and expenses and related disclosure contingent liabilities the dates the financial statements
These estimates and assumptions must made due certain information used preparation our financial
statements which dependent future events cannot calculated with high degree precision from data
available not capable being readily calculated based generally accepted methodologies The Company
believes that the accounting related revenue recognition product returns and allowances bad debts inventory
valuation goodwill and intangible assets income taxes warranty and installation provisions litigation
retirement plan obligations stock based compensation equity investments and contingencies involves significant
judgments and estimates Actual results for all estimates could differ materially from the estimates and
assumptions used which could have material adverse effect our financial condition and results
operations
The effects climate change could harm the Company business
The Company manufacturing processes for certain its products involve the use chemicals and other
substances that are regulated under various international federal state and local laws governing the environment
the event that any future climate change legislation would require that stricter standards imposed
domestic international environmental regulatory authorities with respect the use and levels possible
emissions from such chemicals and other substances the Company may required make certain changes
and adaptations its manufacturing processes Any such changes could have material adverse effect the
financial statements the Company
Another potential effect climate change increase the severity global weather conditions The
Company manufacturing facilities are located the United States United Kingdom Ireland and Germany
addition the Company manufactures growing percentage its HPLC UPLC and products both
Singapore and Ireland Severe weather and geological conditions events including earthquakes hurricanes
and tsunamis could potentially cause significant damage the Company manufacturing facilities each
these countries The effects such damage and the resulting disruption manufacturing operations could have
material adverse impact the financial results the Company
Item
Unresolved Staff Comments
None
Item
Properties
Waters Corporation operates United States facilities and international facilities including field offices The
Company believes its facilities are suitable and adequate for its current production level and for reasonable
growth over the next several years The Company primary facilities are summarized the table below
Primary Facility Locations
Location
Golden
New Castle
Milford
Taunton
Wakefield
Eden Prairie
Nixa
Sharpsburg
Lindon
New Castle England
Solihull England
Wilmslow England
Quentin France
Huellhorst Germany
Bochum Germany
Budapest Hungary
Wexford Ireland
Ede Netherlands
Etten Leur Netherlands
Brasov Romania
Singapore
Function
Owned Leased
Leased
Owned
Owned
Owned
Leased
Leased
Leased
Leased
Leased
Leased
Owned
Owned
Leased
Owned
Leased
Leased
Owned
Leased
Owned
Leased
Leased
Manufacturing Research Sales and Service Distribution Administration
The Company operates and maintains field offices the United States and field offices abroad addition
sales offices the primary facilities listed above The Company field office locations are listed below
Field Office Locations
United States
International
Irvine
Pleasanton
Wood Dale
Columbia
Beverly
Ann Arbor
Durham
Morrisville
Parsippany
Plymouth Meeting
Bellaire
Australia
Austria
Belgium
Brazil
Canada
Czech Republic
Denmark
Finland
France
Germany
Hungary
India
Ireland
Israel
Italy
Japan
Korea
Malaysia
Mexico
Netherlands
Norway
People Republic China
Portugal
Poland
Puerto Rico
Spain
Sweden
Switzerland
Taiwan
United Kingdom
The Company operates more than one field office within certain states and foreign countries
Item
Legal Proceedings
From time time the Company and its subsidiaries are involved various litigation matters arising the
ordinary course business The Company believes has meritorious arguments its current litigation matters
and believes any outcome either individually the aggregate will not material the Company financial
position results operations both and the Company recorded million litigation
settlement provisions and related costs associated with multiple litigation matters
Item
Mine Safety Disclosures
Not applicable
EXECUTIVE OFFICERS THE REGISTRANT
Officers the Company are elected annually the Board Directors and hold office the discretion the
Board Directors The following persons serve executive officers the Company
Christopher Connell has served Director the Company since September when
assumed the position President and Chief Executive Officer the Company Connell served
Executive Vice President and President Restorative Therapies Group Medtronic plc from August
August From August Connell served the following positions Medtronic plc
Senior Vice President and President Medtronic Diabetes President Medtronic Physio Control Vice
President Sales and Marketing for the Cardiac Rhythm Management business Vice President General
Manager the Patient Management Business Vice President Corporate Strategy Director Investor
Relations and Corporate Development Associate
Mark Beaudouin was appointed Senior Vice President General Counsel and Secretary February
and was Vice President General Counsel and Secretary the Company since April Prior joining
Waters Corporation served Senior Vice President General Counsel and Secretary PAREXEL
International Corporation bio pharmaceutical services company from January April Previously
from May January Beaudouin served several senior legal management positions including
Vice President General Counsel and Secretary International Inc development stage biotechnology
company First Senior Vice President General Counsel and Secretary Baker Inc diversified retail
company and General Counsel and Secretary GenRad Inc high technology test equipment manufacturer
Sherry Buck was appointed Senior Vice President and Chief Financial Officer January
Previously Buck served the Vice President Chief Financial Officer Libbey Inc since August
From Buck held several positions Whirlpool Corporation including Vice President
Finance Chief Financial Officer Global Product and Enterprise Cost Leadership Vice President Finance
Vice President Cost Leadership Vice President Finance International and Vice President Business
Performance Management
Michael Harrington was appointed Senior Vice President Global Markets February
Harrington joined Waters Corporation and has held several senior positions with Waters Corporation
including Vice President Europe and Asia Pacific Operations Senior Director Sales Operations Director
Chemistry Sales and General Manager Phase Separations Prior joining Waters Corporation
Harrington held senior sales positions Celsis Inc
Terrance Kelly was appointed Senior Vice President and President Instruments February
Kelly has served President instruments since February Kelly started his career
finance and accounting ICI joined DuPont held various sales and marketing positions
with DuPont and later Instruments Kelly joined Waters Corporation when Instruments was
acquired
Rohit Khanna was appointed Senior Vice President Applied Technology February
Khanna previously served Vice President Worldwide Marketing and Informatics since and also held
several senior positions with Waters Corporation including Vice President Customer Assurance and Vice
President Data Products Khanna joined Waters Corporation when Dynamic Solutions company
founded and managed Khanna was acquired
Ian King was appointed Senior Vice President Instrument Technology February King
joined Waters and previously served Vice President Separations Technologies and Vice President and
General Manager Consumable Division well variety scientific and management positions Waters
Corporation international subsidiaries Prior joining Waters Corporation King worked Edinburgh
University research scientist
Elizabeth Rae was appointed Senior Vice President Global Human Resources February and
was Vice President Human Resources since October and Vice President Worldwide Compensation
and Benefits since January Rae joined Waters Corporation January Director Worldwide
Compensation Prior joining Waters Corporation she held senior human resources positions retail
healthcare and financial services companies
David Terricciano was appointed Senior Vice President Global Operations February
Terricciano previously served Vice President Global Operations since August Prior joining
Waters Corporation worked Vice President and General Manager Operations for Perkin Elmer
Instruments Previously held variety executive positions Goodrich Aerospace Honeywell Aerospace
and Textron Corporation
PART
Item
Market for Registrant Common Equity Related Stockholder Matters and Issuer Purchases
Equity Securities
The Company common stock registered under the Exchange Act and listed the New York Stock
Exchange under the symbol WAT February the Company had common stockholders
record The Company has not declared paid any dividends its common stock its past three fiscal years
The Company has not made any sales unregistered equity securities the years ended December
Securities Authorized for Issuance under Equity Compensation Plans
Equity compensation plan information incorporated reference from Part III Item Security Ownership
Certain Beneficial Owners and Management and Related Stockholder Matters this document and should
considered integral part this Item
Stock Price Performance Graph
The following performance graph and related information shall not deemed soliciting material
filed with the SEC nor shall such information incorporated reference into any future filing under the
Securities Act amended the Exchange Act except the extent that the Company specifically
incorporates reference into such filing
The following graph compares the cumulative total return invested December the last
day public trading the Company common stock fiscal year through December the last
day public trading the common stock fiscal year the Company common stock the NYSE
Market Index the SIC Code Index and the Index The return the indices calculated assuming
reinvestment dividends during the period presented The Company has not paid any dividends since its IPO
The stock price performance shown the graph below not necessarily indicative future price performance
COMPARISON CUMULATIVE TOTAL RETURN SINCE DECEMBER
AMONG WATERS CORPORATION NYSE MARKET INDEX SIC CODE INDEX
LABORATORY ANALYTICAL INSTRUMENTS AND INDEX
DOLLARS
WATERS CORPORATION
NYSE MARKET INDEX
SIC CODE INDEX
INDEX
WATERS CORPORATION
NYSE MARKET INDEX
SIC CODE INDEX
INDEX
Market for Registrant Common Equity
The quarterly range high and low sales prices for the Company common stock reported the New York
Stock Exchange follows
Price Range
High
Low
For the Quarter Ended
April
July
October
December
April
July
October
December
Purchases Equity Securities the Issuer
The following table provides information about purchases the Company during the three months ended
December equity securities registered the Company under the Exchange Act thousands except
per share data
Average
Price Paid
per Share
Total Number
Shares Purchased
Part Publicly
Announced
Programs
Maximum Dollar
Value Shares
that May Yet
Purchased Under
the Programs
Total
Number
Shares
Purchased
October October
October November
November December
Total
Period
The Company repurchased million common stock related the vesting restricted stock units during
The Company purchased aggregate million shares its outstanding common stock
open market transactions pursuant repurchase program that was announced May the
Program The Program authorized the repurchase million common stock open
market transactions over three year period
Item
Selected Financial Data
The following table sets forth selected historical consolidated financial and operating data for the periods
indicated The statement operations and balance sheet data derived from audited financial statements for the
years and The Company financial statements December and
and for each the three years the period ended December are included Item Financial
Statements and Supplementary Data Part this Form
thousands except per share
and employees data
STATEMENT OPERATIONS
DATA
Net sales
Income from operations before income
taxes
Net income
Net income per basic common share
Weighted average number basic common
shares
Net income per diluted common share
Weighted average number diluted
common shares and equivalents
BALANCE SHEET AND OTHER
DATA
Cash cash equivalents and investments
Working capital including current
maturities debt
Total assets
Long term debt
Stockholders equity
Employees
the Company adopted new accounting guidance related the presentation debt issuance costs
and deferred income taxes both standards have been applied above retrospectively Certain debt issuance
costs have been reclassified from intangible assets and are presented direct deduction from the carrying
value the associated debt Current deferred tax assets and liabilities have been reclassified non current
deferred tax assets and liabilities
Item
Management Discussion and Analysis Financial Condition and Results Operations
Business and Financial Overview
The Company has two operating segments Waters and TA Waters products and services primarily consist
high performance liquid chromatography HPLC ultra performance liquid chromatography UPLC and
together with HPLC referred LC mass spectrometry MS and chemistry consumable products and
related services products and services primarily consist thermal analysis rheometry and calorimetry
instrument systems and service sales The Company products are used pharmaceutical biochemical
industrial nutritional safety environmental academic and governmental customers These customers use the
Company products detect identify monitor and measure the chemical physical and biological composition
materials and predict the suitability and stability fine chemicals pharmaceuticals water polymers
metals and viscous liquids various industrial consumer goods and healthcare products
The Company operating results are follows for the years ended December and
thousands except per share data
Year Ended December
change
Operating income
Operating income sales
Interest expense net
Income from operations before income taxes
Provision for income taxes
Net income
Revenues
Product sales
Service sales
Total net sales
Costs and operating expenses
Cost sales
Selling and administrative expenses
Research and development expenses
Purchased intangibles amortization
Litigation provisions
Acquired process research and development
Net income per diluted common share
the Company sales increased compared The growth was mainly driven
continued strength our pharmaceutical market followed growth our industrial market which includes
sales industrial chemical nutritional safety and environmental customers offset decline sales our
governmental and academic customers Instrument systems produced mid single digit sales growth during
and our chemistry and service businesses continued generate high single digit growth rates due higher
instrument utilization and growing base installed instrument systems Geographically the Company
experienced positive sales growth all major regions world wide basis led Asia which generated
double digit growth during This double digit sales growth rate Asia was primarily attributed strong
demand for the Company products and services China and favorable effect foreign currency translation
Japan Sales growth Europe and the was and respectively the Company
sales grew compared the effect foreign currency translation significantly reduced the sales
growth rate experienced the pharmaceutical and industrial end markets The effect foreign currency
translation negatively impacted sales and across all products and services and
respectively Based current foreign exchange rates the Company expects that foreign currency translation
may negatively affect sales growth Recent acquisitions had minimal impact sales growth both
and
Sales pharmaceutical customers grew and and respectively The increase
was driven the increasing need for global access prescription drugs and the testing newer and more
complex biologic drugs Geographically the growth within our pharmaceutical market was driven doubledigit growth China and Japan while sales growth was driven double digit growth the
China and India offset the negative effects foreign currency translation
Combined sales industrial customers grew and and respectively The growth
was driven the increasing need for food quality and food safety testing and fine chemical applications
Geographically industrial market sales growth was highest Europe followed Asia and offset weakness
the Before the effects foreign currency translation the Company industrial customer sales
grew higher rate than This overall weaker demand from the Company industrial customers
was primarily attributed the decline instrument system sales and the overall soft demand for the
Company products and services the
Combined sales governmental and academic customers decreased and and
respectively result these institutions reducing their spending the Company products and the negative
effects foreign currency translation combined sales governmental and academic customers
grew China and India but declined all other regions combined sales governmental and academic
customers grew the and China but declined all other regions
Instrument system sales increased and and respectively due higher demand for
and instrument systems This strength demand was driven HPLC UPLC ACQUITY ArcTM
QDa and Vion IMS TofTM instrument systems well other systems that incorporate the
Company benchtop tandem quadrupole technologies Recurring revenues combined sales chemistry
consumables and services increased and and respectively result larger installed
base customers and higher billing demand for service sales Foreign currency translation lowered the
recurring revenues
Geographically sales Asia increased and and respectively The sales growth
Asia was result the broad based increase China sales across all product and customer classes and the
favorable effect foreign currency Japan where foreign currency translation increased sales
after decreasing sales Sales the increased after the delivered sales
growth when the Company experienced greater demand for its products and services the
Sales Europe and the rest the world increased and respectively compared
decline both Europe and the rest the world sales The negative effects foreign currency
translation the sales growth Europe and the rest the world was approximately which was
significantly less than the decrease Europe and the decrease the rest the world sales
when the dollar strengthened substantially against all currencies throughout the world
Operating income was million increase compared This increase was
primarily result the effect higher sales volume achieved and the positive impact foreign
currency translation our manufacturing and research and development costs result the
significantly weaker British Pound Operating income increased compared result
higher sales volumes achieved being partly offset million reduction operating income from
the adverse effects foreign currency translation
The Company generated million million and million net cash flows from operations
and respectively The increases operating cash flow each year were primarily result
the increase sales and net income
Cash flows used investing activities included capital expenditures related property plant equipment
and software capitalization million million and million and respectively
September the Company acquired Rubotherm GmbH for approximately million cash and the
Company made payments million and million acquire and license intellectual property during
and respectively These acquisitions did not have significant impact the Company sales and profits
During and the Company issued and sold senior unsecured notes for aggregate principal
amount million and million respectively During and the Company repurchased
million million and million the Company outstanding common stock respectively under
authorized share repurchase programs The Company believes that has the financial flexibility fund these
share repurchases given current cash and investment levels and debt borrowing capacity well invest
research technology and business acquisitions further grow the Company sales and profits
Results Operations
Sales Geography
Geographic sales information presented below for the years ended December and
thousands
Year Ended December
change
Total Asia
Other
Total net sales
Net Sales
United States
Europe
Asia
China
Japan
Asia Other
sales growth the sales was driven increases recurring revenues which were offset
declines instrument systems sales sales increased pharmaceutical customers but declined
non pharmaceutical end markets Europe sales were also driven recurring revenues and primarily
due increases pharmaceutical and industrial customers China achieved strong sales growth all product
and customer classes with double digit growth instrument systems and chemistry
consumables well double digit growth pharmaceutical customers Japan increase sales was
largely driven the benefit foreign currency translation which increased sales The increase sales
the rest Asia was driven instrument systems and chemistry consumables sales
pharmaceutical and industrial customers Sales the rest Asia decreased due the negative effect
foreign currency translation Sales the rest the world were broad based across all product classes
sales increased industrial customers but declined across all other customer classes
the sales growth was broad based across all products and was driven pharmaceutical and
industrial customers Europe sales were broad based across all product and customer classes but
declined result the negative effects foreign currency China achieved strong double digit sales growth
all product and customer classes Japan sales were negatively impacted foreign currency
translation which decreased sales The increase sales the rest Asia was driven
pharmaceutical and industrial customers across all product classes Sales the rest the world
increased pharmaceutical customers but declined across all other customer and product classes The decline
sales the rest the world was significantly attributable reduction customer demand Latin
America caused the strengthening the dollar and the weak Brazilian economy
Waters Products and Services Net Sales
Net sales for Waters products and services are follows for the years ended December and
thousands
Total
Year Ended December
Total
Total
change
Waters instrument systems
Chemistry
Total Waters product sales
Waters service
Total Waters net sales
The increase Waters instrument system sales and technology based both and
primarily attributable higher sales HPLC UPLC ACQUITY Arc QDa and Vion IMS Tof instrument
systems well other systems that incorporate the Company benchtop tandem quadrupole
technologies Chemistry consumables sales increased both and the uptake ACQUITY
columns CORTECS columns and application specific testing kits Waters service sales both and
benefited from increased sales service plans and higher service demand billings higher installed base
customers The effect foreign currency translation had minimal impact Waters sales and
decreased Waters sales across all products and services
Waters sales increased the Europe Asia and the rest the world
Waters sales increased China and were broad based across all product and customer classes Waters sales
Japan increased primarily due the benefit foreign currency translation which increased sales
Waters sales the rest Asia increased and were driven product sales pharmaceutical and
industrial customers offset weakness within governmental and academic markets
Waters sales increased the and Asia while sales decreased Europe and
the rest the world The increase sales the was across all customer classes Waters sales
China increased but decreased Japan due the effects foreign currency translation
Waters sales the rest Asia increased and were driven sales pharmaceutical and industrial
customers
Product and Services Net Sales
Net sales for products and services are follows for the years ended December and
thousands
Year Ended December
Total
Total
instrument systems
service
Total net sales
Total
change
instrument system sales were flat primarily due weaker demand for its instrument systems
The increase instrument system sales growth was primarily attributable TA thermal physical
properties instruments addition TA core thermal analysis instrument systems sales rebounded after
decrease comparison stronger sales service sales increased both and due
sales service plans and billings higher installed base customers The effect foreign currency
translation had minimal impact sales and decreased TA sales Recent acquisitions
added approximately and TA sales and respectively
sales increased both the Americas and Asia and increased Europe sales were
flat the but achieved double digit increase the rest the Americas TA sales Japan
increased with increase due the benefit foreign currency translation
showed sales growth the and Asia excluding Japan but sales declined Europe Japan and the rest
the world result negative foreign currency translation
Cost Sales
The increase cost sales for both and were consistent with the increase sales volumes
cost sales included the benefit weaker British pound which reduced the Company manufacturing
costs when translated into dollars The weakening the British pound began with the announcement that
the would exiting the European Union The effect foreign currency translation benefited cost sales
but increased cost sales
Cost sales are affected many factors including but not limited foreign currency translation
product mix product costs instrument systems and amortization software platforms current foreign
currency exchange rates the Company expects that the impact foreign currency translation may negatively
impact gross profit the benefits from the weakening the British pound are expected offset
the impact the weakening all other major currencies
Selling and Administrative Expenses
Selling and administrative expenses increased and decreased Selling and administrative
expenses and were impacted headcount additions and higher merit compensation costs and the
effect foreign currency translation which lowered selling and administrative expenses and
and respectively addition the Company incurred million stock compensation expense
related the modification certain stock awards upon the retirement senior executives Severance related
costs and were million million and million respectively connection with
reduction workforce the Company incurred million impairment charge related write down
the fair value building held for sale the This building was sold for million cash
percentage net sales selling and administrative expenses were and for
and respectively
Research and Development Expenses
Research and development expenses increased and and respectively Research and
development expenses both and were impacted additional headcount merit compensation and
costs associated with new products and the development new technology initiatives addition the effect
foreign currency translation reduced research and development expenses and and
respectively primarily due the weakening the British pound the Company research and
development costs and research and development expenses also included benefit million
and million respectively from government grant the effect foreign currency translation was
unfavorable and increased expenses
Acquired Process Research and Development
During and the Company incurred charges million and million respectively for acquired
process research and development related milestone payments associated with licensing arrangement for
certain intellectual property relating mass spectrometry technologies yet commercialized and for which
there was future alternative use the acquisition date These licensing arrangements are significantly
related new biologically focused applications well other applications and require the Company make
additional future payments million certain milestones are achieved well royalties future
net sales These future payments may significant and occur over multiple years
Litigation Provision
The Company recorded million litigation settlement provisions and related costs both and
Interest Expense Net
The decreases net interest expense and were primarily attributable higher income earned
increased cash cash equivalents and investment balances
Provision for Income Taxes
The four principal jurisdictions which the Company manufactures are the Ireland the and
Singapore where the marginal effective tax rates were approximately and respectively
December The Company has contractual tax rate Singapore through March
based upon the achievement certain contractual milestones which the Company expects continue meet
The current statutory tax rate Singapore The effect applying the contractual tax rate rather than the
statutory tax rate income from qualifying activities Singapore increased the Company net income
and million million and million respectively and increased the Company net
income per diluted share and respectively
The Company effective tax rate influenced many significant factors including but not limited the
wide range income tax rates jurisdictions which the Company operates sales volumes and profit levels
each tax jurisdiction changes tax laws tax rates and policies the outcome various ongoing tax audit
examinations and the impact foreign currency transactions and translation result variability these
factors the Company effective tax rates the future may not similar the effective tax rates for the current
prior years
The Company effective tax rates were and and respectively The
change the effective tax rates can primarily attributed differences the proportionate amounts pre tax
income recognized jurisdictions with different effective tax rates addition the income tax provision for
included million tax benefit related release valuation allowance certain net operating loss
carryforwards the income tax provision included million tax benefit related the completion
tax audit examinations
Liquidity and Capital Resources
Condensed Consolidated Statements Cash Flows thousands
Year Ended December
Net income
Depreciation and amortization
Stock based compensation
Deferred income taxes
Gain sale assets building impairment
process research and development and other non cash charges
Change accounts receivable
Change inventories
Change accounts payable and other current liabilities
Change deferred revenue and customer advances
Other changes
Net cash provided operating activities
Net cash used investing activities
Net cash used financing activities
Effect exchange rate changes cash and cash equivalents
Increase decrease cash and cash equivalents
Cash Flow from Operating Activities
Net cash provided operating activities was million million and million and
respectively The changes within net cash provided operating activities include the following significant
changes the sources and uses net cash provided operating activities aside from the changes net
income
The changes accounts receivable were primarily attributable timing payments made customers
and timing sales Days sales outstanding was days both December and and days
December
The changes inventory were primarily attributable anticipated annual increases sales volumes
well new product launches
The changes accounts payable and other current liabilities were result timing payments
vendors
Net cash provided from deferred revenue and customer advances results from annual increases new
service contracts higher installed base customers renew annual service contracts
Other changes were attributable variation the timing various provisions expenditures prepaid
income taxes and accruals other current assets other assets and other liabilities addition the
Company made one time contributions totaling million certain Non pension plans during
Cash Used Investing Activities
Net cash used investing activities totaled million million and million and
respectively Additions fixed assets and capitalized software were million million and million
and respectively During and the Company purchased billion
billion and billion investments respectively while billion billion and billion
investments matured respectively Business acquisitions net cash acquired were million million and
million during and respectively the Company sold equity investment for
million and the Company received million cash from the sale building the During
and the Company made payments million and million respectively acquire and license
intellectual property
Cash Used Financing Activities
The Company issued and sold senior unsecured notes with aggregate principal amount million and
million May and June respectively The proceeds from the issuance the senior unsecured
notes were used repay existing debt and for general corporate purposes Interest the fixed rate
senior unsecured notes payable semi annually each year Interest the floating rate senior unsecured notes
payable quarterly The Company may prepay all some the senior unsecured notes any time amount
not less than the aggregate principal amount outstanding plus the applicable make whole amount
prepayment premium for Series senior unsecured notes the event change control the Company
defined the note purchase agreement the Company may required prepay the senior unsecured notes
price equal the principal amount thereof plus accrued and unpaid interest These senior unsecured
notes require that the Company comply with interest coverage ratio test not less than for any period
four consecutive fiscal quarters and leverage ratio test not more than the end any fiscal
quarter addition these senior unsecured notes include customary negative covenants affirmative covenants
representations and warranties and events default
June the Company entered into credit agreement that provides for billion revolving facility
and million term loan facility April Waters Corporation entered into amendment this
agreement the Amended Credit Agreement The Amended Credit Agreement provides for increase the
revolving commitments from billion billion and extends the maturity the original credit agreement
from June until April The Company plans use future proceeds from the revolving facility
for general corporate purposes
The interest rates applicable the Amended Credit Agreement are the Company option equal either
the alternate base rate calculated daily which rate per annum equal the greatest the prime rate
effect such day the federal funds effective rate effect such day plus per annum the
adjusted LIBO rate such day such day not business day the immediately preceding business day for
deposit dollars with maturity one month plus per annum the applicable month
adjusted LIBO rate each case plus interest rate margin based upon the Company leverage ratio which
can range between basis points for alternate base rate loans and between basis points and basis
points for adjusted LIBO rate loans The facility fee the Amended Credit Agreement ranges between basis
points and basis points The Amended Credit Agreement requires that the Company comply with interest
coverage ratio test not less than the end any fiscal quarter for any period four consecutive
fiscal quarters and leverage ratio test not more than the end any fiscal quarter addition the
Amended Credit Agreement includes negative covenants affirmative covenants representations and warranties
and events default that are customary for investment grade credit facilities
During and the Company net debt borrowings increased million million
and million respectively December the Company had total million
outstanding debt which consisted million outstanding senior unsecured notes million borrowed
under term loan facility under the Amended Credit Agreement million borrowed under revolving credit
facility under the Amended Credit Agreement and less than million borrowed under various other short term
lines credit offset million unamortized debt issuance costs December million
the outstanding portion the revolving facility was classified short term liabilities the consolidated balance
sheet due the fact that the Company expects repay this portion the borrowing under the revolving line
credit within the next twelve months The remaining million the outstanding portion the revolving
facility was classified long term liabilities the consolidated balance sheet this portion not expected
repaid within the next twelve months December the Company had total amount available
borrow under the Amended Credit Agreement million after outstanding letters credit
December the Company was compliance with all debt covenants
May the Company Board Directors authorized the Company repurchase million
its outstanding common stock over three year period During and the Company
repurchased million million and million shares the Company outstanding common stock cost
million million and million respectively under the May authorization and other
previously announced programs December the Company had total million authorized for
future repurchases under the May plan addition the Company repurchased million million and
million common stock related the vesting restricted stock units during the years ended December
and respectively
The Company received million million and million proceeds from the exercise stock
options and the purchase shares pursuant the Company employee stock purchase plan and
respectively
The Company had cash cash equivalents and investments million December The
majority the Company cash cash equivalents and investments are generated from foreign operations with
million held foreign subsidiaries December which million was held currencies
other than the dollar Due the fact that most the Company cash cash equivalents and investments are
held outside the the Company must manage and maintain sufficient levels cash flow the
fund operations and capital expenditures service debt interest finance potential acquisitions and continue
the authorized stock repurchase program the These cash requirements are managed the
Company cash flow from operations and the use the Company revolving credit facility
Management believes the date this report that its financial position particularly the along
with expected future cash flows from earnings based historical trends and the ability raise funds from
external sources and the borrowing capacity from existing committed credit facilities will sufficient
service debt and fund working capital and capital spending requirements authorized share repurchase amounts
and potential acquisitions addition there have been recent significant changes the Company financial
position nor are there any anticipated changes that warrant material adjustment related indefinitely
reinvested foreign earnings
Contractual Obligations and Commercial Commitments
The following summary the Company known contractual obligations December
thousands
Total
Payments Due Year
After
Notes payable and debt
Interest senior
unsecured notes
Long term debt
Operating leases
Total
Does not include normal purchases made the ordinary course business and uncertain tax positions
discussed below
The interest rates applicable the Amended Credit Agreement are the Company option equal either
the alternate base rate calculated daily which rate per annum equal the greatest the prime rate
effect such day the federal funds effective rate effect such day plus per annum
the adjusted LIBO rate such day such day not business day the immediately preceding
business day for deposit dollars with maturity one month plus per annum the
applicable month adjusted LIBO rate each case plus interest rate margin based upon the
Company leverage ratio which can range between basis points for alternate base rate loans and
between basis points and basis points for adjusted LIBO rate loans The facility fee the
Amended Credit Agreement ranges between basis points and basis points The Amended Credit
Agreement requires that the Company comply with interest coverage ratio test not less than
the end any fiscal quarter for any period four consecutive fiscal quarters and leverage ratio test
not more than the end any fiscal quarter addition the Amended Credit Agreement
includes negative covenants affirmative covenants representations and warranties and events default that
are customary for investment grade credit facilities December the Company was
compliance with all such covenants
The following summary the Company known commercial commitments December
thousands
Amount Commitments Expiration Per Period
Total
Letters credit
After
From time time the Company and its subsidiaries are involved various litigation matters arising the
ordinary course business The Company believes has meritorious arguments its current litigation matters
and believes any outcome either individually the aggregate will not material the Company financial
position results operations
The Company has long term liabilities for deferred employee compensation including pension and
supplemental executive retirement plans The payments related the supplemental retirement plan are not
included above since they are dependent upon when the employee retires leaves the Company and whether the
employee elects lump sum annuity payments During fiscal year the Company expects contribute
approximately million million the Company defined benefit plans
The Company has contingent consideration for earnout pertaining the Medimass acquisition The
earnout payments are not included above since they are dependent upon many factors that cannot predicted
with any certainty The estimated fair value the contingent consideration December
million
The Company licenses certain technology and software from third parties Future minimum license fees
payable under existing license agreements December are immaterial The Company enters into
licensing arrangements with third parties that require future milestone royalty payments contingent upon
future events Upon the achievement certain milestones existing agreements the Company could make
additional future payments million well royalties future net sales not possible
predict with reasonable certainty whether these milestones will achieved the timing for achievement
result these potential payments are not included the table above
The Company accounts for its uncertain tax return reporting positions accordance with the accounting
standards for income taxes which require financial statement reporting the expected future tax consequences
uncertain tax reporting positions the presumption that all concerned tax authorities possess full knowledge
those tax reporting positions well all the pertinent facts and circumstances but prohibit any
discounting unrecognized tax benefits associated with those reporting positions for the time value money
The Company classified interest and penalties related unrecognized tax benefits component the
provision for income taxes all the Company unrecognized tax benefits accrued December
were become recognizable the future the Company would record total reduction approximately
million its income tax provision
With limited exceptions the Company longer subject tax audit examinations significant
jurisdictions for the years ended before December However carryforward tax attributes that were
generated years beginning before January may still adjusted upon examination tax
authorities the attributes are utilized The Company continuously monitors the lapsing statutes limitations
potential tax assessments for related changes the measurement unrecognized tax benefits related net
interest and penalties and deferred tax assets and liabilities
During the year ended December the Company concluded tax audit disputes outside the that
part related matters for which the Company had recorded net uncertain tax benefits The resolution these
tax disputes resulted million reduction the measurement its unrecognized tax benefits for the year
ended December
During the year ended December the Company concluded tax audit disputes that part
related matters for which the Company had recorded net uncertain tax benefits The resolution these tax
disputes resulted million reduction the measurement its unrecognized tax benefits and million
decrease its provision for income taxes for the year ended December
December the Company expects record additional reductions the measurement its
unrecognized tax benefits and related net interest and penalties approximately million within the next
twelve months due potential tax audit settlements and the lapsing statutes limitations potential tax
assessments The Company does not expect record any other material reductions the measurement its
unrecognized tax benefits within the next twelve months
The Company has not paid any dividends and has plans this time pay any dividends the future
Off Balance Sheet Arrangements
The Company has not created and not party any special purpose off balance sheet entities for the
purpose raising capital incurring debt operating parts its business that are not consolidated the extent
the Company ownership interest therein into the consolidated financial statements The Company has not
entered into any transactions with unconsolidated entities whereby has subordinated retained interests
derivative instruments other contingent arrangements that expose the Company material continuing risks
contingent liabilities any other obligation under variable interest unconsolidated entity that provides
financing liquidity market risk credit risk support the Company
The Company enters into standard indemnification agreements its ordinary course business Pursuant
these agreements the Company indemnifies holds harmless and agrees reimburse the indemnified party for
losses suffered incurred the indemnified party generally the Company business partners customers
connection with patent copyright other intellectual property infringement claims any third party with
respect its current products well claims relating property damage personal injury resulting from the
performance services the Company its subcontractors The maximum potential amount future
payments the Company could required make under these indemnification agreements unlimited
Historically the Company costs defend lawsuits settle claims relating such indemnity agreements have
been minimal and management accordingly believes the estimated fair value these agreements immaterial
Critical Accounting Policies and Estimates
Summary
The preparation consolidated financial statements requires the Company make estimates and judgments that
affect the reported amounts assets liabilities revenues and expenses and related disclosure contingent
liabilities Critical accounting policies are those that are central the presentation the Company financial
condition and results operations that require management make estimates about matters that are highly
uncertain and that would have material impact the Company results operations given changes the
estimate that are reasonably likely occur from period period use different estimates that reasonably
could have been used the current period ongoing basis the Company evaluates its policies and
estimates The Company bases its estimates historical experience and various other assumptions that are
believed reasonable under the circumstances the results which form the basis for making judgments
about the carrying values assets and liabilities that are not readily apparent from other sources Actual amounts
may differ from these estimates under different assumptions conditions There are other items within the
Company consolidated financial statements that require estimation but are not deemed critical defined
above Changes estimates used these and other items could potentially have material impact the
Company consolidated financial statements
Revenue Recognition
Sales products and services are generally recorded based product shipment and performance service
respectively The Company deferred revenue the consolidated balance sheets consists the obligation
instrument service contracts and customer payments received advance prior shipment the instrument
December the Company had current and long term deferred revenue liabilities million and
million respectively Revenue recognized when all the following revenue recognition criteria are met
persuasive evidence arrangement exists delivery performance has occurred the vendor fee fixed
determinable collectibility reasonably assured and applicable upon acceptance when acceptance criteria
with contractual cash holdback are specified Shipping and handling costs are included cost sales net
amounts invoiced the customer per the order
Product shipments including those for demonstration evaluation and service contracts are not recorded
revenue until valid purchase order master agreement received specifying fixed terms and prices The
Company generally recognizes product revenue when legal title has transferred and risk loss passes the
customer The Company generally structures its sales arrangements shipping point international equivalent
and accordingly recognizes revenue upon shipment some cases destination based shipping terms are
included sales arrangements which cases revenue generally recognized when the products arrive the
customer site
The Company method revenue recognition for certain products requiring installation accounted for
accordance with multiple element revenue recognition accounting standards With respect the installation
obligations the larger the contractual cash holdback the best estimate selling price the installation
service deferred when the product shipped and revenue recognized multiple element arrangement
when installation complete The Company determines the best estimate selling price installation based
upon number factors including hourly service billing rates and estimated installation hours
Instrument service contracts are typically billed the beginning the maintenance period The amount
the service contract amortized ratably revenue over the instrument maintenance period There are
deferred costs associated with the service contract the cost the service recorded when the service
performed revenue recognized until all revenue recognition criteria have been met
Sales standalone software are accounted for accordance with the accounting standards for software
revenue recognition The Company software arrangements typically include software licenses and maintenance
contracts Software license revenue recognized when persuasive evidence arrangement exists delivery
has occurred the fee fixed determinable collection probable and there are significant post delivery
obligations remaining The revenue associated with the software maintenance contract recognized ratably over
the maintenance term Unspecified rights software upgrades are typically sold part the maintenance
contract when and available basis The Company uses the residual method allocate software revenue
when transaction includes multiple elements and vendor specific objective evidence fair value undelivered
elements exists Under the residual method the fair value the undelivered element maintenance deferred
and the remaining portion the arrangement fee allocated the delivered element software license and
recognized revenue
Returns and customer credits are infrequent and are recorded reduction sales Rights return are not
included sales arrangements Revenue associated with products that contain specific customer acceptance
criteria not recognized before the customer acceptance criteria are satisfied Discounts from list prices are
recorded reduction sales
Loss Provisions Accounts Receivable and Inventory
The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability its
customers make required payments the financial condition the Company customers were deteriorate
resulting impairment their ability make payments additional allowances may required The
Company does not request collateral from its customers but collectibility enhanced through the use credit
card payments and letters credit The Company assesses collectibility based number factors including
but not limited past transaction history with the customer the credit worthiness the customer industry
trends and the macro economic environment Historically the Company has not experienced significant bad debt
losses Sales returns and allowances are estimates future product returns related current period revenue
Material differences may result the amount and timing revenue for any period management made
different judgments utilized different estimates for sales returns and allowances for doubtful accounts The
Company accounts receivable balance December was million net allowances for doubtful
accounts and sales returns million
The Company values all its inventories the lower cost market first first out basis
FIFO The Company estimates revisions its inventory valuations based technical obsolescence
historical demand projections future demand including that the Company current backlog orders and
industry and market conditions actual future demand market conditions are less favorable than those
projected management additional write downs may required The Company inventory balance
December was recorded its net realizable value million which net write downs
million
Long Lived Assets Intangible Assets and Goodwill
The Company assesses the impairment identifiable intangibles long lived assets and goodwill whenever
events changes circumstances indicate that the carrying value may not recoverable Factors the Company
considers important which could trigger impairment include but are not limited the following
significant underperformance relative historical projected future operating results particularly
pertains capitalized software and patent costs
significant negative industry economic trends competitive products and technologies and
significant changes developments strategic technological collaborations legal matters which affect
the Company capitalized patents purchased technology trademarks and intellectual properties such
licenses
When the Company determines that the carrying value individual intangible asset long lived asset
goodwill may not recoverable based upon the existence one more the above indicators estimate
undiscounted future cash flows produced that intangible asset long lived asset goodwill including its
eventual residual value compared the carrying value determine whether impairment exists the event
that such cash flows are not expected sufficient recover the carrying amount the asset the asset
written down its estimated fair value Net intangible assets long lived assets and goodwill amounted
million million and million respectively December
The Company performs annual impairment reviews its goodwill January each year For goodwill
impairment review purposes the Company has two reporting units Waters and The Company currently does
not expect record impairment charge the foreseeable future however there can assurance that
the time future reviews are completed material impairment charge will not recorded The factors that could
cause material goodwill impairment charge the future include but are not limited the following
significant decline the Company projected revenue earnings cash flows
significant adverse change legal factors business climate
significant decline the Company stock price the stock price comparable companies
adverse action assessment regulator and
unanticipated competition
Income Taxes
part the process preparing the consolidated financial statements the Company required estimate its
income taxes each the jurisdictions which operates This process involves the Company estimating its
actual current tax exposure taking into account the amount timing and character taxable income tax
deductions and credits and assessing changes tax laws regulations agreements and treaties Differing
treatment items for tax and accounting purposes such depreciation amortization and inventory reserves
result deferred tax assets and liabilities which are included within the consolidated balance sheets the event
that actual results differ from these estimates the Company adjusts these estimates future periods such
changes could materially impact the Company financial position and results operations
The accounting standards for income taxes require that company continually evaluate the necessity
establishing changing valuation allowance for deferred tax assets depending whether more likely than
not that the actual benefit those assets will realized future periods
Uncertain Tax Positions
The Company accounts for its uncertain tax return reporting positions accordance with the accounting
standards for income taxes which require financial statement reporting the expected future tax consequences
uncertain tax reporting positions the presumption that all concerned tax authorities possess full knowledge
those tax reporting positions well all the pertinent facts and circumstances but prohibit any
discounting unrecognized tax benefits associated with those reporting positions for the time value money
The Company classified interest and penalties related unrecognized tax benefits component the
provision for income taxes December the Company had unrecognized tax benefits million
The Company has been granted contractual tax rate Singapore that requires the achievement
certain operational and financial milestones that the Company expects meet the extent not already achieved
December and maintain through least March part the Company determination
uncertain tax positions the Company regularly assesses its progress against these operational and financial
milestone targets determine whether the milestones can reasonably achieved These milestones were
negotiated with the Singaporean tax authorities and established based the Company historical financial
performance the anticipated customer end market demand particularly certain regions the world and the
Company anticipated future operating plans These assessments require significant judgments and estimates
about the Company ability meet the milestone targets for the following types objectives reaching and
maintaining annual revenue and business spending targets meeting capital expenditures targets attaining and
sustaining employment targets and establishing local research and development and service center The
Company regularly monitors its actual and forecasted sales and operating results against these milestones and the
Company makes the determination whether the future forecasted financial results are most likely
achieved These milestones are very similar nature the previous Singaporean tax holiday contractual
agreements that the Company successfully completed These milestones are not required met until
December the earliest which gives the Company sufficient time make any necessary adjustments
its operating plans achieve the milestones
Currently the Company has determined that more likely than not realize the contractual tax rate
Singapore and has not recognized uncertain tax benefit its balance sheet related the achievement
the contractual milestones Singapore However these milestones can significantly influenced the
business climate Singapore and the Company overall financial performance and the event that the
Company determines that the milestone targets are not expected met the Company would longer able
record tax benefit contractual tax rate income earned Singapore from and after the April
start date the contract period such time the Company would record income tax charge the
affected Singapore income earned back April the Singapore statutory tax rate currently
with corresponding income tax liability recorded the balance sheet For the year ended the effect
applying the contractual tax rate rather than the statutory tax rate income from qualifying activities
Singapore increased the Company net income and net income per diluted share million and
respectively
Warranty
Product warranties are recorded the time revenue recognized for certain product shipments While the
Company engages extensive product quality programs and processes including actively monitoring and
evaluating the quality its component suppliers the Company warranty obligation affected product
failure rates material usage and service delivery costs incurred correcting product failure Should actual
product failure rates material usage service delivery costs differ from the Company previous estimates
revisions the estimated warranty liability would required December the Company warranty
liability was million
Litigation
described Item Legal Proceedings Part this Form the Company party various
pending litigation matters With respect each pending claim management determines whether can
reasonably estimate whether loss probable and the probable range that loss and when
management has determined with respect particular claim both that loss probable and that can
reasonably estimate the range that loss the Company records charge equal either its best estimate that
loss the lowest amount that probable range loss The Company will disclose additional exposures when
the range loss subject considerable uncertainty
Pension and Other Retirement Benefits
Assumptions used determining projected benefit obligations and the fair values plan assets for the
Company pension plans and other retirement benefits are evaluated periodically management Changes
assumptions are based relevant Company data Critical assumptions such the discount rate used measure
the benefit obligations and the expected long term rate return plan assets are evaluated and updated
annually The Company has assumed that the weighted average expected long term rate return plan assets
will for its benefit plans and for its non benefit plans
the end each year the Company determines the discount rate that reflects the current rate which the
pension liabilities could effectively settled The Company utilized Milliman Bond Matching model
determine the discount rate for its benefit plans The Company determined the discount rate for its non
benefit plans based the analysis the Mercer Pension Discount Curve for high quality investments
December that best matched the timing the plan future cash flows for the period maturity the
pension benefits Once the interest rates were determined the plan cash flow was discounted the spot interest
rate back the measurement date December the Company determined the weighted average
discount rate for the benefit plans and for the non benefits plans
one quarter percentage point increase the assumed long term rate return would decrease the
Company net periodic benefit cost for the Waters Retirement Plan less than million one quarter
percentage point increase the discount rate would decrease the Company net periodic benefit cost for the
Waters Retirement Plan less than million
Stock based Compensation
The accounting standards for stock based compensation require that all share based payments employees
recognized the statements operations based their fair values The Company has used the Black Scholes
option pricing model and Monte Carlo simulation model determine the fair value its stock option awards
and performance stock unit awards respectively Under the fair value recognition provisions this statement
share based compensation cost measured the grant date based the value the award and recognized
expense over the vesting period Determining the fair value share based awards the grant date requires
judgment including estimating stock price volatility and employee stock option exercise behaviors actual
results differ significantly from these estimates stock based compensation expense and the Company results
operations could materially impacted stock based compensation expense recognized the consolidated
statements operations based awards that ultimately are expected vest the amount the expense has
been reduced for estimated forfeitures These accounting standards require forfeitures estimated the time
grant and revised necessary subsequent periods actual forfeitures differ from those estimates
Forfeitures are estimated based historical experience factors change and the Company employs different
assumptions the application these accounting standards the compensation expense that the Company
records future periods may differ significantly from what the Company has recorded the current period The
Company recognizes the expense using the straight line attribution method
December unrecognized compensation costs and related weighted average lives over which
the costs will amortized were follows millions
Unrecognized
Compensation
Costs
Weighted Average
Life Years
Stock options
Restricted stock units
Performance stock units
Restricted stock
Total
Business Combinations and Asset Acquisitions
The Company accounts for business acquisitions under the accounting standards for business combinations The
results each acquisition are included the Company consolidated results the acquisition date and the
purchase price acquisition allocated tangible and intangible assets and assumed liabilities based
their estimated fair values Any excess the fair value consideration transferred over the estimated fair values
the net assets acquired recognized goodwill Acquired process research and development IPR
included business combination capitalized indefinite lived intangible asset Development costs
incurred after the acquisition are expensed incurred and acquired IPR tested for impairment annually
until completion the acquired programs Upon commercialization this indefinite lived intangible asset then
accounted for finite lived intangible asset and amortized straight line basis over its estimated useful life
subject periodic impairment reviews the research and development project abandoned the indefinitelived asset charged expense Legal costs due diligence costs business valuation costs and all other business
acquisition costs are expensed when incurred
The Company also acquires intellectual property through licensing arrangements These arrangements often
require upfront payments and may include additional milestone royalty payments contingent upon certain
future events IPR acquired asset acquisition opposed business combination expensed
immediately unless there alternative future use Subsequent payments made for the achievement
milestones are evaluated determine whether they have alternative future use should expensed
Payments made third parties subsequent commercialization are capitalized and amortized over the
remaining useful life the related asset and are classified intangible assets
Contingent Consideration
addition the initial cash consideration paid acquire Medimass the Company obligated make
additional earnout payments based royalty due future sales products containing the REIMS
technology accordance with the accounting standards for business combinations the Company determines the
fair value the liability for contingent consideration each reporting date using probability weighted
discounted cash flow model Subsequent changes the fair value the contingent consideration liability are
recorded the results operations The fair value the contingent consideration liability associated with
future earnout payments based several factors including estimated future results and discount rate
reflective the Company creditworthiness change any these unobservable inputs can significantly
change the fair value the contingent consideration Although there contractual limit total future
undiscounted contingent consideration payments were estimated million December based
the Company best estimate the earnout based future sales certain products through
Recent Accounting Standard Changes and Developments
Information regarding recent accounting standard changes and developments incorporated reference from
Part Item Financial Statements and Supplementary Data this document and should considered
integral part this Item See Note the Notes the Consolidated Financial Statements for recently adopted
and issued accounting standards
Item Quantitative and Qualitative Disclosures About Market Risk
The Company global company that operates over countries and result the Company net sales
cost sales operating expenses and balance sheet amounts are significantly impacted fluctuations foreign
currency exchange rates The Company exposed currency price risk foreign currency exchange rate
fluctuations when translates its non dollar foreign subsidiaries financial statements into dollars and
when any the Company subsidiaries purchase sell products services currency other than its own
currency
The Company principal strategy managing exposure changes foreign currency exchange rates
naturally hedge the foreign currency denominated liabilities the Company balance sheet against
corresponding assets the same currency such that any changes liabilities due fluctuations foreign
currency exchange rates are typically offset corresponding changes assets
The Company does not specifically enter into any derivatives that hedge foreign currency denominated
assets liabilities commitments its balance sheet other than portion certain third party accounts
receivable and accounts payable and the Company net worldwide intercompany receivables and payables
which are eliminated consolidation The Company periodically aggregates its net worldwide balances
currency and then enters into foreign currency exchange contracts that mature within days hedge portion
the remaining balance minimize some the Company currency price risk exposure The foreign currency
exchange contracts are not designated for hedge accounting treatment
Principal hedged currencies include the Euro Japanese yen British pound Mexican peso and Brazilian real
December and the Company held foreign currency exchange contracts with notional
amounts totaling million million and million respectively
The Company foreign currency exchange contracts included the consolidated balance sheets are
classified follows thousands
Other current assets
Other current liabilities
December
December
The following summary the activity included cost sales the statements operations related
the foreign currency exchange contracts thousands
Year Ended December
Realized losses gains closed contracts
Unrealized losses gains open contracts
Cumulative net pre tax losses
Assuming hypothetical adverse change year end exchange rates strengthening the
dollar the fair market value the foreign currency exchange contracts outstanding December
would decrease pre tax earnings approximately million
The Company cash and cash equivalents are not subject significant interest rate risk due the short
maturities these instruments The Company cash equivalents represent highly liquid investments with
original maturities days less primarily bank deposits treasury bill money market funds and
commercial paper December the carrying value the Company cash and cash equivalents
approximated fair value
The Company exposed the risk interest rate fluctuations from the investments cash generated
from operations Investments with maturities greater than days are classified investments and are held
primarily treasury bills dollar denominated treasury bills and commercial paper bank deposits and
corporate debt securities The Company maintains cash balances various operating accounts excess
federally insured limits and foreign subsidiary accounts currencies other than the dollar
December and million out million and million out million
respectively the Company total cash cash equivalents and investments were held foreign subsidiaries
and may subject material tax effects distribution legal entities addition million out
million and million out million cash cash equivalents and investments were held
currencies other than the dollar December and respectively December the
Company has holdings auction rate securities commercial paper issued structured investment
vehicles
Assuming hypothetical adverse change year end exchange rates strengthening the
dollar the fair market value the Company cash cash equivalents and investments held currencies
other than the dollar December would decrease approximately million which the
majority would recorded foreign currency translation other comprehensive income within stockholders
equity
Item Financial Statements and Supplementary Data
Management Report Internal Control Over Financial Reporting
Our management responsible for establishing and maintaining adequate internal control over financial
reporting such term defined Rules under the Exchange Act Because its
inherent limitations internal control over financial reporting may not prevent detect misstatements Also
projections any evaluation effectiveness future periods are subject the risk that controls may become
inadequate because changes conditions that the degree compliance with the policies procedures
may deteriorate
Under the supervision and with the participation our management including our chief executive officer
and chief financial officer conducted evaluation the effectiveness our internal control over financial
reporting based the framework Internal Control Integrated Framework issued the Committee
Sponsoring Organizations the Treadway Commission COSO Based our evaluation under the framework
Internal Control Integrated Framework our management including our chief executive officer and
chief financial officer concluded that our internal control over financial reporting was effective
December
The effectiveness our internal control over financial reporting December has been audited
PricewaterhouseCoopers LLP independent registered public accounting firm stated their report
which included herein
Report Independent Registered Public Accounting Firm
the Board Directors and Stockholders Waters Corporation
our opinion the accompanying consolidated balance sheets and the related consolidated statements
operations comprehensive income stockholders equity and cash flows present fairly all material respects
the financial position Waters Corporation and its subsidiaries December and December
and the results their operations and their cash flows for each the three years the period ended
December conformity with accounting principles generally accepted the United States America
addition our opinion the financial statement schedule valuation and qualifying accounts appearing the
index appearing under Item presents fairly all material respects the information set forth therein
when read conjunction with the related consolidated financial statements Also our opinion the Company
maintained all material respects effective internal control over financial reporting December
based criteria established Internal Control Integrated Framework issued the Committee
Sponsoring Organizations the Treadway Commission COSO The Company management responsible for
these financial statements and financial statement schedule for maintaining effective internal control over
financial reporting and for its assessment the effectiveness internal control over financial reporting
included the accompanying Management Report Internal Control over Financial Reporting Our
responsibility express opinions these financial statements the financial statement schedule and the
Company internal control over financial reporting based our integrated audits conducted our audits
accordance with the standards the Public Company Accounting Oversight Board United States Those
standards require that plan and perform the audits obtain reasonable assurance about whether the financial
statements are free material misstatement and whether effective internal control over financial reporting was
maintained all material respects Our audits the financial statements included examining test basis
evidence supporting the amounts and disclosures the financial statements assessing the accounting principles
used and significant estimates made management and evaluating the overall financial statement presentation
Our audit internal control over financial reporting included obtaining understanding internal control over
financial reporting assessing the risk that material weakness exists and testing and evaluating the design and
operating effectiveness internal control based the assessed risk Our audits also included performing such
other procedures considered necessary the circumstances believe that our audits provide
reasonable basis for our opinions
company internal control over financial reporting process designed provide reasonable assurance
regarding the reliability financial reporting and the preparation financial statements for external purposes
accordance with generally accepted accounting principles company internal control over financial reporting
includes those policies and procedures that pertain the maintenance records that reasonable detail
accurately and fairly reflect the transactions and dispositions the assets the company provide reasonable
assurance that transactions are recorded necessary permit preparation financial statements accordance
with generally accepted accounting principles and that receipts and expenditures the company are being made
only accordance with authorizations management and directors the company and iii provide reasonable
assurance regarding prevention timely detection unauthorized acquisition use disposition the
company assets that could have material effect the financial statements
Because its inherent limitations internal control over financial reporting may not prevent detect
misstatements Also projections any evaluation effectiveness future periods are subject the risk that
controls may become inadequate because changes conditions that the degree compliance with the
policies procedures may deteriorate
PricewaterhouseCoopers LLP
Boston Massachusetts
February
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
December
thousands except per share data
ASSETS
Current assets
Cash and cash equivalents
Investments
Accounts receivable net
Inventories
Other current assets
Total current assets
Property plant and equipment net
Intangible assets net
Goodwill
Other assets
Total assets
LIABILITIES AND STOCKHOLDERS EQUITY
Current liabilities
Notes payable and debt
Accounts payable
Accrued employee compensation
Deferred revenue and customer advances
Accrued income taxes
Accrued warranty
Other current liabilities
Total current liabilities
Long term liabilities
Long term debt
Long term portion retirement benefits
Long term income tax liabilities
Other long term liabilities
Total long term liabilities
Total liabilities
Commitments and contingencies Notes and
Stockholders equity
Preferred stock par value per share shares authorized none issued
December and December
Common stock par value per share shares authorized
and shares issued and shares outstanding
December and December respectively
Additional paid capital
Retained earnings
Treasury stock cost and shares December and
December respectively
Accumulated other comprehensive loss
Total stockholders equity
Total liabilities and stockholders equity
The accompanying notes are integral part the consolidated financial statements
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OPERATIONS
Year Ended December
thousands except per share data
Revenues
Product sales
Service sales
Total net sales
Costs and operating expenses
Cost product sales
Cost service sales
Selling and administrative expenses
Research and development expenses
Purchased intangibles amortization
Litigation provisions Note
Acquired process research and development Note
Total costs and operating expenses
Operating income
Interest expense
Interest income
Income from operations before income taxes
Provision for income taxes
Net income
Net income per basic common share
Weighted average number basic common shares
Net income per diluted common share
Weighted average number diluted common shares and equivalents
The accompanying notes are integral part the consolidated financial statements
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS COMPREHENSIVE INCOME
Year Ended December
thousands
Net income
Other comprehensive loss
Foreign currency translation
Unrealized gains losses investments before income taxes
Income tax benefit
Unrealized gains losses investments net tax
Retirement liability adjustment before reclassifications
Amounts reclassified selling and administrative expenses
Retirement liability adjustment before income taxes
Income tax benefit expense
Retirement liability adjustment net tax
Other comprehensive loss
Comprehensive income
The accompanying notes are integral part the consolidated financial statements
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS CASH FLOWS
Year Ended December
thousands
Cash flows from operating activities
Net income
Adjustments reconcile net income net cash provided
operating activities
Provisions for doubtful accounts accounts receivable
Stock based compensation
Deferred income taxes
Depreciation
Amortization intangibles
Building impairment
Gain sale assets
process research and development and other
non cash charges
Change operating assets and liabilities net acquisitions
Increase accounts receivable
Increase inventories
Increase other current assets
Increase other assets
Increase decrease accounts payable and other current
liabilities
Increase deferred revenue and customer advances
Increase decrease other liabilities
Net cash provided operating activities
Cash flows from investing activities
Additions property plant equipment and software
capitalization
Business acquisitions net cash acquired
Payments for intellectual property licenses
Purchases investments
Maturities and sales investments
Proceeds from sale assets
Net cash used investing activities
Cash flows from financing activities
Proceeds from debt issuances
Payments debt
Payments debt issuance costs
Proceeds from stock plans
Purchases treasury shares
Excess tax benefit related stock option plans
Payments for proceeds from derivative contracts
Net cash used financing activities
Effect exchange rate changes cash and cash equivalents
Increase decrease cash and cash equivalents
Cash and cash equivalents beginning period
Cash and cash equivalents end period
Supplemental cash flow information
Income taxes paid
Interest paid
The accompanying notes are integral part the consolidated financial statements
WATERS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS STOCKHOLDERS EQUITY
Balance December
Net income
Other comprehensive loss
Issuance common stock
for employees
Employee Stock Purchase
Plan
Stock options
exercised
Tax benefit related stock
option plans
Treasury stock
Stock based
compensation
Balance December
Net income
Other comprehensive loss
Issuance common stock
for employees
Employee Stock Purchase
Plan
Stock options
exercised
Tax benefit related stock
option plans
Treasury stock
Stock based
compensation
Balance December
Net income
Other comprehensive loss
Issuance common stock
for employees
Employee Stock Purchase
Plan
Stock options
exercised
Tax benefit related stock
option plans
Treasury stock
Stock based
compensation
Balance December
Accumulated
Other
Comprehensive
Income Loss
Number
Common
Shares
Common
Stock
Additional
Paid
Capital
Retained
Treasury
Earnings
Stock
thousands
Total
Stockholders
Equity
The accompanying notes are integral part the consolidated financial statements
NOTES CONSOLIDATED FINANCIAL STATEMENTS
Description Business and Organization
Waters Corporation the Company analytical instrument manufacturer that primarily designs
manufactures sells and services high performance liquid chromatography HPLC ultra performance liquid
chromatography UPLC and together with HPLC referred LC and mass spectrometry MS
technology systems and support products including chromatography columns other consumable products and
comprehensive post warranty service plans These systems are complementary products that are frequently
employed together MS and sold integrated instrument systems using common software platform
standard technique and utilized broad range industries detect identify monitor and measure the
chemical physical and biological composition materials and purify full range compounds
instruments are used drug discovery and development including clinical trial testing the analysis proteins
disease processes known proteomics nutritional safety analysis and environmental testing
instruments combine liquid phase sample introduction and separation system with mass spectrometric
compound identification and quantification addition the Company designs manufactures sells and services
thermal analysis rheometry and calorimetry instruments through its TA product line These instruments are
used predicting the suitability and stability fine chemicals pharmaceuticals water polymers metals and
viscous liquids for various industrial consumer goods and healthcare products well for life science
research The Company also developer and supplier software based products that interface with the
Company instruments well other suppliers instruments and are typically purchased customers part
the instrument system
Basis Presentation and Summary Significant Accounting Policies
Use Estimates
The preparation consolidated financial statements conformity with generally accepted accounting principles
GAAP requires the Company make estimates and judgments that affect the reported amounts assets
liabilities revenues and expenses and related disclosure contingent liabilities the dates the financial
statements ongoing basis the Company evaluates its estimates including those related revenue
recognition product returns and allowances bad debts inventory valuation goodwill and intangible assets
income taxes warranty and installation provisions litigation retirement plan obligations stock based
compensation equity investments and contingencies The Company bases its estimates historical experience
and various other assumptions that are believed reasonable under the circumstances the results which
form the basis for making judgments about the carrying values assets and liabilities that are not readily
apparent from other sources Actual amounts may differ from these estimates under different assumptions
conditions
Risks and Uncertainties
The Company subject risks common companies the analytical instrument industry including but not
limited global economic and financial market conditions fluctuations foreign currency exchange rates
fluctuations customer demand development its competitors new technological innovations costs
developing new technologies levels debt and debt service requirements risk disruption dependence key
personnel protection and litigation proprietary technology shifts taxable income between tax jurisdictions
and compliance with regulations the Food and Drug Administration and similar foreign regulatory
authorities and agencies
Principles Consolidation
The consolidated financial statements include the accounts the Company and its subsidiaries which are wholly
owned The Company consolidates entities which owns controls fifty percent more the voting
shares All inter company balances and transactions have been eliminated
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
Translation Foreign Currencies
The functional currency each the Company foreign operating subsidiaries the local currency that
particular country except for the Company subsidiaries Hong Kong Singapore and the Cayman Islands
where the underlying transactional cash flows are denominated currencies other than the respective local
currency domicile The functional currency the Hong Kong Singapore and Cayman Islands subsidiaries
the dollar based the respective entity cash flows
For most the Company foreign operations assets and liabilities are translated into dollars
exchange rates prevailing the balance sheet date while revenues and expenses are translated average
exchange rates prevailing during the period Any resulting translation gains losses are included accumulated
other comprehensive income the consolidated balance sheets The Company net sales derived from
operations outside the United States were and and respectively Gains and
losses from foreign currency transactions are included net income the consolidated statements operations
and foreign currency transactions resulted net gain million and net loss million
respectively Gains and losses from foreign currency transactions were not material for
Seasonality Business
The Company typically experiences increase sales the fourth quarter result purchasing habits for
capital goods customers that tend exhaust their spending budgets calendar year end
Cash Cash Equivalents and Investments
Cash equivalents represent highly liquid investments with original maturities days less primarily
bank deposits treasury bill money market funds and commercial paper Investments with longer maturities
are classified investments and are held primarily treasury bills dollar denominated treasury bills
and commercial paper bank deposits and corporate debt securities
Investments are classified available for sale accordance with the accounting standards for investments
debt and equity securities All available for sale securities are recorded fair market value and any unrealized
holding gains and losses the extent deemed temporary are included accumulated other comprehensive
income stockholders equity net the related tax effects any adjustment fair value reflects decline
the value the investment the Company considers all available evidence evaluate the extent which the
decline other than temporary and marks the investment market through charge the statement
operations The Company classifies its investments exclusive those categorized cash equivalents
The Company maintains cash balances various operating accounts excess federally insured limits
and foreign subsidiary accounts currencies other than the dollar December and
million out million and million out million respectively the Company
total cash cash equivalents and investments were held foreign subsidiaries and may subject material tax
effects distribution legal entities addition million out million and million out
million cash cash equivalents and investments were held currencies other than the dollar
December and respectively
Accounts Receivable and Allowance for Doubtful Accounts
Trade accounts receivable are recorded the invoiced amount and not bear interest The allowance for
doubtful accounts the best estimate the amount probable credit losses the existing accounts receivable
The allowance based number factors including historical experience and the customer
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
worthiness The allowance for doubtful accounts reviewed least quarterly basis Past due balances over
days and over specified amount are reviewed individually for collectibility Account balances are charged
against the allowance when the Company determines probable that the receivable will not recovered The
Company does not have any off balance sheet credit exposure related its customers The allowance for sales
returns the best estimate the amount future product returns related current period revenue and based
historical experience
The following summary the activity the Company allowance for doubtful accounts and sales
returns for the years ended December and thousands
Allowance for Doubtful Accounts and Sales Returns
Balance
Beginning Period
Additions
Deductions
Balance
End
Period
Concentration Credit Risk
The Company sells its products and services significant number large and small customers throughout the
world with net sales the pharmaceutical industry approximately and
None the Company individual customers accounted for more than annual Company sales
The Company performs continuing credit evaluations its customers and generally does
not require collateral but certain circumstances may require letters credit deposits Historically the
Company has not experienced significant bad debt losses
Inventory
The Company values all its inventories the lower cost market first first out basis FIFO
Income Taxes
Deferred income taxes are recognized for temporary differences between the financial statement and income tax
basis assets and liabilities using tax rates effect for the years which the differences are expected
reverse valuation allowance provided offset any net deferred tax assets based upon the available
evidence more likely than not that some all the deferred tax assets will not realized Appropriate
long term liabilities have also been recorded recognize uncertain tax return reporting positions
Property Plant and Equipment
Property plant and equipment are recorded cost Expenditures for maintenance and repairs are charged
expense while the costs significant improvements are capitalized Depreciation provided using the straightline method over the following estimated useful lives buildings fifteen thirty years building
improvements five ten years leasehold improvements the shorter the economic useful life life
lease and production and other equipment three ten years Upon retirement sale the cost the assets
disposed and the related accumulated depreciation are eliminated from the consolidated balance sheets and
related gains losses are reflected the consolidated statements operations
Asset Impairments
The Company reviews its long lived assets for impairment accordance with the accounting standards for
property plant and equipment Whenever events circumstances indicate that the carrying amount asset
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
may not recoverable the Company evaluates the fair value the asset relying number factors
including but not limited operating results business plans economic projections and anticipated future cash
flows Any change the carrying amount asset result the Company evaluation recorded the
consolidated statements operations
Business Combinations and Asset Acquisitions
The Company accounts for business acquisitions under the accounting standards for business combinations The
results each acquisition are included the Company consolidated results the acquisition date and the
purchase price acquisition allocated tangible and intangible assets and assumed liabilities based
their estimated fair values Any excess the fair value consideration transferred over the estimated fair values
the net assets acquired recognized goodwill Acquired process research and development IPR
included business combination capitalized indefinite lived intangible asset Development costs
incurred after the acquisition are expensed incurred and acquired IPR tested for impairment annually
until completion the acquired programs Upon commercialization this indefinite lived intangible asset then
accounted for finite lived intangible asset and amortized straight line basis over its estimated useful life
subject periodic impairment reviews the research and development project abandoned the indefinitelived asset charged expense Legal costs due diligence costs business valuation costs and all other business
acquisition costs are expensed when incurred
The Company also acquires intellectual property through licensing arrangements These arrangements often
require upfront payments and may include additional milestone royalty payments contingent upon certain
future events IPR acquired asset acquisition opposed business combination expensed
immediately unless there alternative future use Subsequent payments made for the achievement
milestones are evaluated determine whether they have alternative future use should expensed
Payments made third parties subsequent commercialization are capitalized and amortized over the
remaining useful life the related asset and are classified intangible assets
Goodwill and Other Intangible Assets
The Company tests for goodwill impairment using fair value approach the reporting unit level annually
earlier event occurs circumstances change that would more likely than not reduce the fair value
reporting unit below its carrying amount Additionally the Company performs annual goodwill impairment
assessment for its reporting units January each year The goodwill and other intangible assets accounting
standards define reporting unit operating segment one level below operating segment discrete
financial information prepared and reviewed management For goodwill impairment review purposes the
Company has two reporting units Waters and Goodwill allocated the reporting units the time
acquisition Under the impairment test reporting unit carrying amount exceeds its estimated fair value
goodwill impairment recognized the extent that the carrying amount goodwill exceeds the implied fair
value the goodwill The fair value reporting units was estimated using discounted cash flows technique
which includes certain management assumptions such estimated future cash flows estimated growth rates and
discount rates
The Company intangible assets include purchased technology capitalized software development costs
costs associated with acquiring Company patents trademarks and intellectual properties such licenses debt
issuance costs and acquired IPR Purchased intangibles are recorded their fair market values the
acquisition date and amortized over their estimated useful lives ranging from one fifteen years Other
intangibles are amortized over period ranging from one ten years Debt issuance costs are amortized over the
life the related debt Acquired IPR amortized from the date completion the acquired program over
its estimated useful life IPR and indefinite lived intangibles are tested annually for impairment
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
Software Development Costs
The Company capitalizes internal and external software development costs for products offered for sale
accordance with the accounting standards for the costs software sold leased otherwise marketed
Capitalized costs are amortized cost sales over the period economic benefit which approximates
straight line basis over the estimated useful lives the related software products generally three ten years
The Company capitalized million and million direct expenses that were related the development
software and respectively Net capitalized software included intangible assets totaled
million both December and See Note Goodwill and Other Intangibles
The Company capitalizes internal software development costs for internal use accordance with the
accounting standards for goodwill and other intangible assets Capitalized internal software development costs
are amortized over the period economic benefit which approximates straight line basis over ten years Net
capitalized internal software included property plant and equipment totaled million both December
and
Other Investments
The Company accounts for its investments that represent less than twenty percent ownership and for which the
Company does not have significant influence using the accounting standards for investments debt and equity
securities Investments for which the Company does not have the ability exercise significant influence and for
which there not readily determinable market value are accounted for under the cost method accounting
The Company periodically evaluates the carrying value its investments accounted for under the cost method
accounting and carries them the lower cost estimated net realizable value For investments which the
Company owns controls between twenty and forty nine percent the voting shares over which exerts
significant influence over operating and financial policies the equity method accounting used The
Company share net income losses equity investments included the consolidated statements
operations and was not material any period presented
During the year ended December the Company sold equity investment that was accounted for
using the equity method accounting and was included other assets the consolidated balance sheet for
million cash The investment had carrying value million which resulted gain the sale
million This investment had balance million December and the Company has longterm investments remaining December
Fair Value Measurements
accordance with the accounting standards for fair value measurements and disclosures certain the
Company assets and liabilities are measured fair value recurring basis December and
Fair values determined Level inputs utilize observable data such quoted prices active markets
Fair values determined Level inputs utilize data points other than quoted prices active markets that are
observable either directly indirectly Fair values determined Level inputs utilize unobservable data points
for which there little market data which require the reporting entity develop its own assumptions
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The following table represents the Company assets and liabilities measured fair value recurring
basis December thousands
Total
December
Quoted Prices
Active
Markets
for Identical
Assets
Level
Significant
Other
Observable
Inputs
Level
Significant
Unobservable
Inputs
Level
Assets
Treasury securities
Foreign government securities
Corporate debt securities
Time deposits
Equity securities
Waters Restoration Plan assets
Foreign currency exchange contracts
Total
Liabilities
Contingent consideration
Foreign currency exchange contracts
Total
The following table represents the Company assets and liabilities measured fair value recurring
basis December thousands
Total
December
Quoted Prices
Active
Markets
for Identical
Assets
Level
Significant
Other
Observable
Inputs
Level
Significant
Unobservable
Inputs
Level
Assets
Treasury securities
Foreign government securities
Corporate debt securities
Time deposits
Equity securities
Other cash equivalents
Waters Restoration Plan assets
Foreign currency exchange contracts
Total
Liabilities
Contingent consideration
Foreign currency exchange contracts
Total
Fair Value Restoration Plan Assets
The Restoration Plan nonqualified defined contribution plan and and the assets were
held registered mutual funds The Company has revised the classification the Restoration Plan assets
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
from Level Level December correct the classification The Company concluded that the
error was not material the prior period financial statements
Fair Value Cash Equivalents Investment and Foreign Currency Exchange Contracts
The fair values the Company cash equivalents investments and foreign currency exchange contracts are
determined through market and observable sources and have been classified Level These assets and
liabilities have been initially valued the transaction price and subsequently valued typically utilizing thirdparty pricing services The pricing services use many inputs determine value including reportable trades
benchmark yields credit spreads broker dealer quotes current spot rates and other industry and economic
events The Company validates the prices provided third party pricing services reviewing their pricing
methods and obtaining market values from other pricing sources After completing these validation procedures
the Company did not adjust override any fair value measurements provided third party pricing services
December and
Fair Value Contingent Consideration
The fair value the Company liability for contingent consideration relates the July acquisition
Medimass Research Development and Service Kft and determined using probability weighted discounted
cash flow model which uses significant unobservable inputs and has been classified Level Subsequent
changes the fair value the contingent consideration liability are recorded the results operations The
fair value the contingent consideration liability associated with future earnout payments based several
factors including the estimated future results and discount rate that reflects both the likelihood achieving the
estimated future results and the Company creditworthiness change any these unobservable inputs can
significantly change the fair value the contingent consideration Although there contractual limit the fair
value future contingent consideration payments was estimated million and million December
and December respectively based the Company best estimate the earnout based
future sales certain products some which are currently development through The change fair
value since December primarily due reduction the future revenue projections offset the
change time value money
Fair Value Other Financial Instruments
The Company cash accounts receivable accounts payable and variable interest rate debt are recorded cost
which approximates fair value due their short term nature The carrying value the Company fixed interest
rate debt was million and million December and respectively The fair value the
Company fixed interest rate debt was estimated using discounted cash flow models based estimated current
rates offered for similar debt under current market conditions for the Company The fair value the Company
fixed interest rate debt was estimated million and million December and
respectively using Level inputs
Derivative Transactions
The Company global company that operates over countries and result the Company net sales
cost sales operating expenses and balance sheet amounts are significantly impacted fluctuations foreign
currency exchange rates The Company exposed currency price risk foreign currency exchange rate
fluctuations when translates its non dollar foreign subsidiaries financial statements into dollars and
when any the Company subsidiaries purchase sell products services currency other than its own
currency
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The Company principal strategy managing exposure changes foreign currency exchange rates
naturally hedge the foreign currency denominated liabilities the Company balance sheet against
corresponding assets the same currency such that any changes liabilities due fluctuations foreign
currency exchange rates are typically offset corresponding changes assets
The Company does not specifically enter into any derivatives that hedge foreign currency denominated
assets liabilities commitments its balance sheet other than portion certain third party accounts
receivable and accounts payable and the Company net worldwide intercompany receivables and payables
which are eliminated consolidation The Company periodically aggregates its net worldwide balances
currency and then enters into foreign currency exchange contracts that mature within days hedge portion
the remaining balance minimize some the Company currency price risk exposure The foreign currency
exchange contracts are not designated for hedge accounting treatment
Principal hedged currencies include the Euro Japanese yen British pound Mexican peso and Brazilian real
December and the Company held foreign currency exchange contracts with notional
amounts totaling million million and million respectively
The Company foreign currency exchange contracts included the consolidated balance sheets are
classified follows thousands
December
December
Other current assets
Other current liabilities
The following summary the activity included cost sales the statements operations related
the foreign currency exchange contracts thousands
Year Ended December
Realized losses gains closed contracts
Unrealized losses gains open contracts
Cumulative net pre tax losses
Stockholders Equity
May the Company Board Directors authorized the Company repurchase million its
outstanding common stock over three year period During and the Company repurchased
million million and million shares the Company outstanding common stock cost
million million and million respectively under the May authorization and other
previously announced programs December the Company repurchased aggregate
million shares cost million under the May repurchase program and has total
million authorized for future repurchases addition the Company repurchased million million and
million common stock related the vesting restricted stock units during the years ended December
and respectively The Company believes that has the financial flexibility fund these share
repurchases given current cash levels and debt borrowing capacity well invest research technology
and business acquisitions further grow the Company sales and profits
Revenue Recognition
Sales products and services are generally recorded based product shipment and performance service
respectively The Company deferred revenue the consolidated balance sheets consists the obligation
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
instrument service contracts and customer payments received advance prior shipment the instrument
Revenue recognized when all the following revenue recognition criteria are met persuasive evidence
arrangement exists delivery performance has occurred the vendor fee fixed determinable collectibility
reasonably assured and applicable upon acceptance when acceptance criteria with contractual cash
holdback are specified Shipping and handling costs invoiced the customer are included net sales while the
costs associated with shipping and handling are included cost sales
Product shipments and service contracts are not recorded revenue until valid purchase order master
agreement received specifying fixed terms and prices The Company generally recognizes product revenue
when legal title has transferred and risk loss passes the customer The Company generally structures its
sales arrangements shipping point international equivalent and accordingly recognizes revenue upon
shipment some cases destination based shipping terms are included sales arrangements which cases
revenue generally recognized when the products arrive the customer site
The Company method revenue recognition for certain products requiring installation accounted for
accordance with multiple element revenue recognition accounting standards With respect the installation
obligations the larger the contractual cash holdback the best estimate selling price the installation
service deferred when the product shipped and revenue recognized multiple element arrangement
when installation complete The Company determines the best estimate selling price installation based
upon number factors including hourly service billing rates and estimated installation hours
Instrument service contracts are typically billed the beginning the maintenance period The amount
the service contract amortized ratably revenue over the instrument maintenance period There are
deferred costs associated with the service contract the cost the service recorded when the service
performed revenue recognized until all revenue recognition criteria have been met
Sales standalone software are accounted for accordance with the accounting standards for software
revenue recognition The Company software arrangements typically include software licenses and maintenance
contracts Software license revenue recognized when persuasive evidence arrangement exists delivery
has occurred the fee fixed determinable collection probable and there are significant post delivery
obligations remaining The revenue associated with the software maintenance contract recognized ratably over
the maintenance term Unspecified rights software upgrades are typically sold part the maintenance
contract when and available basis The Company uses the residual method allocate software revenue
when transaction includes multiple elements and vendor specific objective evidence fair value undelivered
elements exists Under the residual method the fair value the undelivered element maintenance deferred
and the remaining portion the arrangement fee allocated the delivered element software license and
recognized revenue
Returns and customer credits are infrequent and are recorded reduction sales Rights return are not
included sales arrangements Revenue associated with products that contain specific customer acceptance
criteria not recognized before the customer acceptance criteria are satisfied Discounts from list prices are
recorded reduction sales
Product Warranty Costs
The Company accrues estimated product warranty costs the time sale which are included cost sales
the consolidated statements operations While the Company engages extensive product quality programs
and processes including actively monitoring and evaluating the quality its component suppliers the
Company warranty obligation affected product failure rates material usage and service delivery costs
incurred correcting product failure The amount the accrued warranty liability based historical
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
information such past experience product failure rates number units repaired and estimated costs
material and labor The liability reviewed for reasonableness least quarterly
The following summary the activity the Company accrued warranty liability for the years ended
December and thousands
Balance
Beginning Period
Accruals for
Warranties
Settlements
Made
Balance
End Period
Accrued warranty liability
Advertising Costs
All advertising costs are expensed incurred and are included selling and administrative expenses the
consolidated statements operations Advertising expenses were million for both and and were
million for
Research and Development Expenses
Research and development expenses are comprised costs incurred performing research and development
activities including salaries and benefits facilities costs overhead costs contract services and other outside
costs Research and development expenses are expensed incurred During and the Company
incurred million and million charges respectively for acquired process research and development
related the licensing certain intellectual property relating mass spectrometry technologies yet
commercialized and for which there was future alternative use the acquisition date These licensing
arrangements are significantly related new biologically focused applications well other applications
and require the Company make additional future payments million certain milestones are
achieved well royalties future net sales
Stock Based Compensation
The Company has two stock based compensation plans which are described Note Stock Based
Compensation
Earnings Per Share
accordance with the earnings per share accounting standards the Company presents two earnings per share
EPS amounts Income per basic common share based income available common shareholders and the
weighted average number common shares outstanding during the periods presented Income per diluted
common share includes additional dilution from potential common stock such stock issuable pursuant the
exercise stock options outstanding
Retirement Plans
The Company sponsors various retirement plans which are described Note Retirement Plans
Comprehensive Income
The Company accounts for comprehensive income accordance with the accounting standards for
comprehensive income which establish the accounting rules for reporting and displaying comprehensive income
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
These standards require that all components comprehensive income reported financial statement that
displayed with the same prominence other financial statements
Recently Adopted Accounting Standards
August accounting guidance was issued which defines management responsibility assess entity
ability continue going concern each annual and interim reporting period and requires additional
disclosures certain circumstances This guidance was effective the three month period ended December
and for annual and interim periods thereafter The adoption this standard did not have impact the
Company financial position results operations cash flows
May accounting guidance was issued which allows practical expedient for the measurement
certain investments using the net asset value per share the investment The guidance also exempts investments
using this practical expedient from categorization within the fair value hierarchy This guidance requires
retrospective application and effective for annual and interim reporting periods beginning after December
The adoption this guidance removed certain retirement plan assets from the fair value hierarchy and the
prior period presentation has been updated conform with the current period presentation see Note
Retirement Plans for further details
Recently Issued Accounting Standards
May amended accounting guidance was issued regarding the recognition revenue from contracts with
customers The objective this guidance significantly enhance comparability and clarify principles
revenue recognition practices across entities industries jurisdictions and capital markets This guidance was
originally effective for annual and interim reporting periods beginning after December however the
Financial Accounting Standards Board FASB amended the standard August delay the effective
period date one year annual and interim periods beginning after December Adoption prior
December not permitted March the FASB clarified the implementation guidance
principal versus agent considerations and April clarification was made regarding certain aspects
identifying performance obligations and licensing implementation guidance May additional guidance
was issued related disclosure remaining performance obligations well other amendments guidance
collectibility non cash consideration and the presentation sales and other similar taxes collected from
customers The Company does not intend early adopt this accounting standard and will apply the modifiedretrospective method The Company currently evaluating the potential impact that the adoption this standard
will have the Company financial position results operations and cash flows
July accounting guidance was issued which clarifies the measurement inventory The new
guidance requires inventory measured the lower cost and net realizable value Net realizable value
the estimated selling prices the ordinary course business less reasonably predictable costs completion
disposal and transportation This guidance effective for annual and interim periods beginning after
December The Company currently does not expect that the adoption this standard will have
material effect the Company financial position results operations and cash flows
January accounting guidance was issued which primarily affects the classification and
measurement certain financial instruments principally equity investments and certain financial liabilities
Under the new guidance there will longer available for sale classification for equity securities with
readily determinable fair values Changes the fair value equity investments will recognized through
earnings Equity investments carried cost should adjusted for changes observable prices applicable
and qualitatively assessed for impairment annually Changes the fair value financial liabilities under the fair
value option due instrument specific credit risk will recognized separately other comprehensive income
The new guidance also requires financial assets and financial liabilities presented separately and grouped
measurement category the notes the financial statements This guidance effective for annual and interim
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
reporting periods beginning after December and early adoption certain provisions this guidance
permitted The Company currently does not expect that the adoption this standard will have material effect
the Company financial position results operations and cash flows
February accounting guidance was issued regarding the accounting for leases This new
comprehensive lease standard amends various aspects existing accounting guidance for leases The core
principle the new guidance will require lessees present the assets and liabilities that arise from leases
their balance sheets This guidance effective for annual and interim reporting periods beginning after
December and early adoption permitted The Company expects that the adoption this standard will
have material effect the Company balance sheet classifications however not expected have
overall material impact the Company financial position results operations and cash flows
March accounting guidance was issued which simplifies the accounting for share based payment
transactions including the income tax consequences classification awards either equity liabilities and
classification the statement cash flows This guidance effective for annual and interim reporting periods
beginning after December and early adoption permitted The Company expects that the adoption
this standard may have material impact the Company financial position results operations and cash
flows the tax benefits excess compensation costs that are currently recorded equity will included
the Company results operations after adoption this standard addition the tax benefits excess
compensation costs which are currently included inflow from financing activities will included
operating activities after adoption this standard Furthermore the impact this standard after adoption
dependent employee stock option exercise activity which not within the Company control
June accounting guidance was issued that modifies the recognition credit losses related
financial assets such debt securities trade receivables net investments leases off balance sheet credit
exposures and other financial assets that have the contractual right receive cash Current guidance requires the
recognition credit loss when considered probable that loss event was incurred The new guidance
requires the measurement expected credit losses based upon relevant information including historical
experience current conditions and reasonable and supportable forecasts that affect the collectability the asset
such expected credit losses may recognized sooner under the new guidance due the broader range
information that will required determine credit loss estimates The new guidance also amends the current
other than temporary impairment model used for debt securities classified available for sale When the fair
value available for sale debt security below its amortized cost the new guidance requires the total
unrealized loss bifurcated into its credit and non credit components Any expected credit losses
subsequent recoveries will recognized earnings and any changes not considered credit related will continue
recognized within other comprehensive income This guidance effective for annual and interim periods
beginning after December The Company currently does not expect that the adoption this standard
will have material effect the Company financial position results operations and cash flows
August accounting guidance was issued that clarifies the classification certain cash flows The
new guidance addresses eight specific areas where current accounting guidance either unclear does not
specifically address classification issues This guidance effective for annual and interim periods beginning
after December and early adoption permitted The Company currently evaluating the potential
impact that the adoption this standard will have the Company cash flows
October accounting guidance was issued regarding intra entity transfers assets other than
inventory The new guidance eliminates the deferral tax effects intra entity transfers other than inventory
and requires entity recognize the income tax consequences when the transfer occurs This guidance
effective for annual and interim periods beginning after December and early adoption permitted The
Company currently evaluating the potential impact that the adoption this standard will have the
Company financial position results operations and cash flows
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
January accounting guidance was issued that clarifies the definition business The new
guidance provides more robust framework use determining when set assets and activities
business thus narrowing the definition and the amount transactions accounted for business combinations
This guidance effective for annual and interim periods beginning after December and early
application permitted under certain circumstances The Company currently evaluating the potential impact
that the adoption this standard will have the Company financial position results operations and cash
flows
January accounting guidance was issued that simplifies the accounting for goodwill impairment
The guidance eliminates step the goodwill impairment test which requires hypothetical purchase price
allocation This guidance effective for annual and interim periods beginning after December and early
adoption permitted The Company currently does not expect that the adoption this standard will have
material effect the Company financial position results operations and cash flows
Marketable Securities
The Company marketable securities within cash equivalents and investments included the consolidated
balance sheets are detailed follows thousands
Amortized
Cost
December
Unrealized Unrealized
Gain
Loss
Fair
Value
Treasury securities
Foreign government securities
Corporate debt securities
Time deposits
Equity securities
Total
Amounts included
Cash equivalents
Investments
Total
Amortized
Cost
December
Unrealized Unrealized
Gain
Loss
Fair
Value
Treasury securities
Foreign government securities
Corporate debt securities
Time deposits
Equity securities
Total
Amounts included
Cash equivalents
Investments
Total
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The estimated fair value marketable debt securities maturity date follows thousands
December
December
Due one year less
Due after one year through three years
Total
Realized gains and losses sales investments were not material and
Inventories
Inventories are classified follows thousands
December
Raw materials
Work progress
Finished goods
Total inventories
During and the Company recorded inventory related excess and obsolescence provisions
million million and million respectively
Property Plant and Equipment
Property plant and equipment consist the following thousands
December
Land and land improvements
Buildings and leasehold improvements
Production and other equipment
Construction progress
Total property plant and equipment
Less accumulated depreciation and amortization
Property plant and equipment net
During and the Company retired and disposed approximately million million
and million property plant and equipment respectively most which was fully depreciated and
longer use Gains disposal were immaterial for the years ended December and During
the Company recorded million impairment charge related write down the fair value building
the which was designated held for sale During the Company sold the building for million
cash which resulted gain the sale million
Acquisitions
September the Company acquired all the outstanding stock Rubotherm GmbH Rubotherm
manufacturer gravimetric analysis systems for approximately million cash million which was paid
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
closing and additional million paid after closing settle certain liabilities Rubotherm develops and
manufactures analytical test instruments for thermogravimetric and sorption measurements that are used both
industrial and academic research laboratories disciplines that include chemistry material science and
engineering The Rubotherm acquisition will help support and further expand product offerings within TA
thermal analysis business The Company has allocated million the purchase price intangible assets
comprised completed technology which will amortized over ten years The remaining purchase price
million was accounted for goodwill which not deductible for tax purposes
The fair values the assets and liabilities acquired were determined using various income approach
valuation techniques which use Level inputs The following table presents the fair values the acquisition
date determined the Company the assets and liabilities owned and recorded connection with
the acquisition Rubotherm thousands
Accounts receivable and current other assets
Inventory
Property plant and equipment
Intangible assets
Goodwill
Total assets acquired
Accrued expenses and other liabilities
Deferred tax liability
Cash consideration paid
November the Company acquired all the outstanding stock MPE Orbur Group Limited and its
sole operating subsidiary Midland Precision Equipment Company Ltd MPE manufacturer
instrumentation components for million net cash acquired MPE highly skilled manufacturer and
former Waters supplier that produces critical components that support the Company instrument systems
MPE was acquired bring this key supplier house reduce manufacturing costs the future and reduce
risk our supply chain
the fourth quarter the Company acquired certain assets its Malaysian sales and service
distributor for million cash
May the Company acquired the net assets the ElectroForce business the Bose Corporation
ElectroForce manufacturer testing systems for million cash ElectroForce core business the
manufacturing dynamic mechanical testing systems used characterize medical devices biologic and
engineered materials The ElectroForce test instruments are based unique motor designs that are quiet energyefficient scalable and deliver precise performance over wide range force and frequency ElectroForce was
acquired expand TA product offering into new markets while leveraging the technology infrastructure and
customer bases the combined organizations
July the Company acquired the net assets Medimass Research Development and Service Kft
Medimass developer mass spectrometry related technologies with the potential used for variety
applications for million cash addition the Company potentially has pay additional contingent
consideration which had estimated fair value million the closing date The net assets acquired
consist primarily the Rapid Evaporative Ionization Mass Spectrometry REIMS technology including
patent applications software databases and REIMS expertise REIMS ambient pressure surface ionization
technique that when used with mass spectrometry can characterize the molecular topography complex
surfaces such cell membranes The contingent consideration payments are calculated based royalty due
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
future sales products containing the REIMS technology The fair value the contingent consideration
recognized was estimated using probability weighted discounted cash flow model using Level inputs
January the Company acquired all the outstanding stock ULSP ULSP
manufacturer instrumentation components that enable ultra low temperature generation for million cash
ULSP core business the manufacturing and servicing high quality low temperature coolers for thermal
analysis and rheology applications and these products are important accessories for many core instrument
offerings ULSP was acquired bring the manufacturing these devices house and expand the Company
product offering
The principal factor that resulted recognition goodwill these acquisitions that the purchase price
was based part cash flow projections assuming the integration any acquired technology distribution
channels and products with the Company products which considerably greater value than utilizing each
the acquired companies technology customer access products standalone basis The goodwill also
includes value assigned assembled workforce which cannot recognized intangible asset Specifically
the goodwill acquired with MPE and Medimass consists the values assigned the respective workforces and
the future incremental sales synergies anticipated
each acquisition the sellers provided the Company with customary representations warranties and
indemnification which would settled the future and when breach the contractual representation
warranty condition occurs The pro forma effect the ongoing operations for Waters Corporation Rubotherm
MPE the Malaysian sales and service distributor ElectroForce Medimass and ULSP either individually
the aggregate though these acquisitions had occurred the beginning the periods covered this report
was immaterial
Goodwill and Other Intangibles
The carrying amount goodwill was million and million December and
respectively During the year ended December the Company acquisitions increased goodwill
million see Note and the effect foreign currency translation decreased goodwill million
The Company intangible assets included the consolidated balance sheets are detailed follows
thousands
December
December
Gross
Carrying
Amount
Accumulated
Amortization
WeightedAverage
Amortization
Period
Gross
Carrying
Amount
Accumulated
Amortization
WeightedAverage
Amortization
Period
Capitalized software
Purchased intangibles
Trademarks and IPR
Licenses
Patents and other intangibles
years
years
years
years
years
years
years
years
Total
years
years
During the year ended December the Company acquired million purchased intangibles
result the acquisition Rubotherm see Note addition the gross carrying value intangible assets and
accumulated amortization for intangible assets decreased million and million respectively the
year ended December due the effects foreign currency translation Amortization expense for
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
intangible assets was million million and million for the years ended December and
respectively Amortization expense for intangible assets estimated million per year for each
the next five years
Debt
May the Company issued the following senior unsecured notes
Senior Unsecured Notes
Term
Series years
Series years
Series years
Interest Rate
Face Value
millions
Maturity Date
Floating Rate
May
May
May
Series senior unsecured notes bear interest month LIBOR for that floating rate interest period plus
the million proceeds received from the issuance the new senior unsecured notes million
were used repay outstanding portions the revolving facilities Interest the Series and senior unsecured
notes payable semi annually each year Interest Series senior unsecured notes payable quarterly The
Company may prepay all some the senior unsecured notes any time amount not less than the
aggregate principal amount outstanding plus the applicable make whole amount prepayment premium for
Series senior unsecured notes Other provisions for these senior unsecured notes are similar the existing
senior unsecured notes described below
June the Company entered into credit agreement that provides for billion revolving facility
and million term loan facility April Waters Corporation entered into amendment this
agreement the Amended Credit Agreement The Amended Credit Agreement provides for increase the
revolving commitments from billion billion and extends the maturity the original credit agreement
from June until April The Company plans use future proceeds from the revolving facility
for general corporate purposes
The interest rates applicable the Amended Credit Agreement are the Company option equal either
the alternate base rate calculated daily which rate per annum equal the greatest the prime rate
effect such day the federal funds effective rate effect such day plus per annum the
adjusted LIBO rate such day such day not business day the immediately preceding business day for
deposit dollars with maturity one month plus per annum the applicable month
adjusted LIBO rate each case plus interest rate margin based upon the Company leverage ratio which
can range between basis points for alternate base rate loans and between basis points and basis
points for adjusted LIBO rate loans The facility fee the Amended Credit Agreement ranges between basis
points and basis points The Amended Credit Agreement requires that the Company comply with interest
coverage ratio test not less than the end any fiscal quarter for any period four consecutive
fiscal quarters and leverage ratio test not more than the end any fiscal quarter addition the
Amended Credit Agreement includes negative covenants affirmative covenants representations and warranties
and events default that are customary for investment grade credit facilities
December million the outstanding portion the revolving facility was classified
short term liabilities the consolidated balance sheet due the fact that the Company expects repay this
portion the borrowing under the revolving line credit within the next twelve months The remaining
million the outstanding portion the revolving facility was classified long term liabilities the
consolidated balance sheet this portion not expected repaid within the next twelve months
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
December and December the Company had total million and
million outstanding senior unsecured notes respectively Interest the fixed rate senior unsecured notes
payable semi annually each year Interest the floating rate senior unsecured notes payable quarterly The
Company may prepay all some the senior unsecured notes any time amount not less than the
aggregate principal amount outstanding plus the applicable make whole amount prepayment premium for
Series and senior unsecured notes the event change control the Company defined the note
purchase agreement the Company may required prepay the senior unsecured notes price equal
the principal amount thereof plus accrued and unpaid interest These senior unsecured notes require that
the Company comply with interest coverage ratio test not less than for any period four
consecutive fiscal quarters and leverage ratio test not more than the end any fiscal quarter
addition these senior unsecured notes include customary negative covenants affirmative covenants
representations and warranties and events default
The Company had the following outstanding debt December and thousands
December
Foreign subsidiary lines credit
Senior unsecured notes Series due March
Credit agreement
Unamortized debt issuance costs
Total notes payable and debt current
Total long term debt
Total debt
Senior unsecured notes Series due February
Senior unsecured notes Series due March
Senior unsecured notes Series due March
Senior unsecured notes Series due June
Senior unsecured notes Series due June
Senior unsecured notes Series floating rate due June
Senior unsecured notes Series due May
Senior unsecured notes Series floating rate due May
Senior unsecured notes Series due May
Credit agreement
Unamortized debt issuance costs
Series senior unsecured notes bear interest month LIBOR for that floating rate interest period plus
Series senior unsecured notes bear interest month LIBOR for that floating rate interest period plus
December and the Company had total amount available borrow under existing
credit agreements million and million respectively after outstanding letters credit The
weighted average interest rates applicable the senior unsecured notes and credit agreement borrowings
collectively were and December and respectively December the
Company was compliance with all debt covenants
The Company and its foreign subsidiaries also had available short term lines credit totaling million
and million December and respectively for the purpose short term borrowing and
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
issuance commercial guarantees December and the weighted average interest rates
applicable these short term borrowings were and respectively
Annual maturities debt outstanding December are follows thousands
Total
Thereafter
Total
Income Taxes
Income tax data for the years ended December and follows thousands
Year Ended December
The components income from operations before income taxes are
follows
Domestic
Foreign
Total
Year Ended December
The current and deferred components the provision for income taxes
operations are follows
Current
Deferred
Total
The jurisdictional components the provision for income taxes
operations are follows
Federal
State
Foreign
Total
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
Year Ended December
The differences between income taxes computed the United States
statutory rate and the provision for income taxes are summarized
follows
Federal tax computed statutory income tax rate
Settlement tax audits
State income tax net federal income tax benefit
Net effect foreign operations
Other net
Provision for income taxes
The four principal jurisdictions which the Company manufactures are the Ireland the and
Singapore where the marginal effective tax rates were approximately and respectively
December The Company has contractual tax rate qualifying activities Singapore
through March based upon the achievement certain contractual milestones which the Company expects
continue meet The current statutory tax rate Singapore The effect applying the contractual tax
rate rather than the statutory tax rate income from qualifying activities Singapore increased the Company
net income and million million and million respectively and increased the
Company net income per diluted share and respectively
The Company effective tax rates for the years ended December and were
and respectively The change the effective tax rates can primarily attributed differences
the proportionate amounts pre tax income recognized jurisdictions with different effective tax rates
addition the income tax provision for included million tax benefit related release valuation
allowance certain net operating loss carryforwards the income tax provision included million
tax benefit related the completion tax audit examinations
The tax effects temporary differences and carryforwards which give rise deferred tax assets and
deferred tax liabilities are summarized follows thousands
December
Deferred tax assets
Net operating losses and credits
Depreciation
Stock based compensation
Deferred compensation
Revaluation equity investments and licenses
Inventory
Accrued liabilities and reserves
Other
Total deferred tax assets
Valuation allowance
Deferred tax assets net valuation allowance
Deferred tax liabilities
Capitalized software
Amortization
Indefinite lived intangibles
Total deferred tax liabilities
Net deferred tax assets
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
December the Company has provided deferred tax valuation allowance million
which million relates certain foreign net operating losses The Company net deferred tax assets
associated with net operating losses and tax credit carryforwards are approximately million
December which represent the future tax benefit foreign net operating loss carryforwards that not
expire under current law
The income tax benefits associated with non qualified stock option compensation expense recognized for
tax purposes and credited additional paid capital were million million and million for the
years ended December and respectively
December there were unremitted earnings foreign subsidiaries approximately billion
The Company has not provided for income taxes foreign withholding taxes these earnings the
Company current intention permanently reinvest these earnings outside the Because the complexity
and foreign tax rules applicable the distribution earnings from foreign subsidiaries legal
entities the determination the unrecognized deferred tax liability these earnings not practicable Events
that could trigger tax might include acquisitions other investments funded cash distributions loans
from foreign subsidiary
The Company accounts for its uncertain tax return reporting positions accordance with the accounting
standards for income taxes which require financial statement reporting the expected future tax consequences
uncertain tax reporting positions the presumption that all concerned tax authorities possess full knowledge
those tax reporting positions well all the pertinent facts and circumstances but prohibit any
discounting unrecognized tax benefits associated with those reporting positions for the time value money
The Company classified interest and penalties related unrecognized tax benefits component the
provision for income taxes
The following summary the activity the Company unrecognized tax benefits for the years ended
December and thousands
Balance the beginning the period
Changes resulting from completion tax examinations
Other changes uncertain tax benefits
Balance the end the period
With limited exceptions the Company longer subject tax audit examinations significant
jurisdictions for the years ended before December However carryforward tax attributes that were
generated years beginning before January may still adjusted upon examination tax
authorities the attributes are utilized The Company continuously monitors the lapsing statutes limitations
potential tax assessments for related changes the measurement unrecognized tax benefits related net
interest and penalties and deferred tax assets and liabilities
During the year ended December the Company concluded tax audit disputes outside the that
part related matters for which the Company had recorded net uncertain tax benefits The resolution these
tax disputes resulted million reduction the measurement its unrecognized tax benefits for the year
ended December
During the year ended December the Company concluded tax audit disputes that part
related matters for which the Company had recorded net uncertain tax benefits The resolution these tax
disputes resulted million reduction the measurement its unrecognized tax benefits and million
decrease its provision for income taxes for the year ended December
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
December the Company expects record additional reductions the measurement its
unrecognized tax benefits and related net interest and penalties approximately million within the next
twelve months due potential tax audit settlements and the lapsing statutes limitations potential tax
assessments The Company does not expect record any other material reductions the measurement its
unrecognized tax benefits within the next twelve months
Litigation
From time time the Company and its subsidiaries are involved various litigation matters arising the
ordinary course business The Company believes has meritorious arguments its current litigation matters
and believes any outcome either individually the aggregate will not material the Company financial
position results operations cash flows both and the Company recorded million
litigation settlement provisions and related costs The accrued patent litigation expense other current
liabilities the consolidated balance sheets December and
Other Commitments and Contingencies
Lease agreements expiring various dates through cover buildings office equipment and automobiles
Rental expense was million for the year ended December and million for each the years
ended December and Future minimum rents payable December under
non cancelable leases with initial terms exceeding one year are follows thousands
and thereafter
The Company licenses certain technology and software from third parties Future minimum license fees
payable under existing license agreements December are immaterial for the years ended
December and thereafter The Company enters into licensing arrangements with third parties that
require future milestone royalty payments contingent upon future events Upon the achievement certain
milestones existing agreements the Company could make additional future payments million
well royalties future net sales
The Company enters into standard indemnification agreements its ordinary course business Pursuant
these agreements the Company indemnifies holds harmless and agrees reimburse the indemnified party for
losses suffered incurred the indemnified party generally the Company business partners customers
connection with patent copyright other intellectual property infringement claims any third party with
respect its current products well claims relating property damage personal injury resulting from the
performance services the Company its subcontractors The maximum potential amount future
payments the Company could required make under these indemnification agreements unlimited
Historically the Company costs defend lawsuits settle claims relating such indemnity agreements have
been minimal and management accordingly believes the estimated fair value these agreements immaterial
Stock Based Compensation
May the Company shareholders approved the Company Equity Incentive Plan Plan
December the Plan has million shares available for grant the form incentive
non qualified stock options stock appreciation rights SARs restricted stock restricted stock units
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
performance stock units other types awards The Company issues new shares common stock upon
exercise stock options restricted stock unit conversion performance stock unit conversion Under the
Plan the exercise price for stock options may not less than the fair market value the underlying stock the
date grant The Plan scheduled terminate May Options generally will expire later
than ten years after the date which they are granted and will become exercisable directed the
Compensation Committee the Board Directors and generally vest equal annual installments over fiveyear period SAR may granted alone conjunction with option other award Shares restricted
stock and restricted stock units and performance stock units may issued under the Plan for such
consideration determined the Compensation Committee the Board Directors December
the Company had stock options restricted stock and restricted and performance stock unit awards
outstanding
May the Company shareholders approved the Employee Stock Purchase Plan under which
eligible employees may contribute their earnings toward the quarterly purchase the Company
common stock The plan makes available million shares the Company common stock which includes the
remaining shares available under the Employee Stock Purchase Plan December million
shares have been issued under both the and Employee Stock Purchase Plans Each plan period lasts
three months beginning January April July and October each year The purchase price for each
share stock the lesser the market price the first day the plan period the market
price the last day the plan period Stock based compensation expense related this plan was million for
each the years ended December and respectively
The Company accounts for stock based compensation costs accordance with the accounting standards for
stock based compensation which require that all share based payments employees recognized the
statements operations based their grant date fair values The Company recognizes the expense using the
straight line attribution method The stock based compensation expense recognized the consolidated
statements operations based awards that ultimately are expected vest therefore the amount expense
has been reduced for estimated forfeitures The stock based compensation accounting standards require
forfeitures estimated the time grant and revised necessary subsequent periods actual forfeitures
differ from those estimates Forfeitures were estimated based historical experience actual results differ
significantly from these estimates stock based compensation expense and the Company results operations
could materially impacted addition the Company employs different assumptions the application
these standards the compensation expense that the Company records the future periods may differ
significantly from what the Company has recorded the current period
The consolidated statements operations for the years ended December and include
the following stock based compensation expense related stock option awards restricted stock awards
restricted stock unit awards performance stock unit awards and the employee stock purchase plan thousands
Cost sales
Selling and administrative expenses
Research and development expenses
Total stock based compensation
During the year ended December the Company recognized million stock compensation
expense related the modification certain stock awards upon the retirement senior executives
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
Stock Options
determining the fair value the stock options the Company makes variety assumptions and estimates
including volatility measures expected yields and expected stock option lives The fair value each option grant
was estimated the date grant using the Black Scholes option pricing model The Company uses implied
volatility its publicly traded options the basis for its estimate expected volatility The Company believes
that implied volatility the most appropriate indicator expected volatility because generally reflective
historical volatility and expectations how future volatility will differ from historical volatility The expected
life assumption for grants based historical experience for the population non qualified stock option
exercises The risk free interest rate the yield currently available Treasury zero coupon issues with
remaining term approximating the expected term used the input the Black Scholes model The relevant data
used determine the value the stock options granted during and are follows
Options Issued and Significant Assumptions Used Estimate Option Fair Values
Options issued thousands
Risk free interest rate
Expected life years
Expected volatility
Expected dividends
Weighted Average Exercise Price and Fair Value Options the Date Grant
Exercise price
Fair value
The following table summarizes stock option activity for the plans for the year ended December
thousands except per share data
Number Shares
Exercise Price
per Share
WeightedAverage
Exercise Price
Outstanding December
Granted
Exercised
Canceled
Outstanding December
The following table details the options outstanding December range exercise prices
thousands except per share data
Exercise
Price Range
Number Shares
Outstanding
WeightedAverage
Exercise Price
Remaining
Contractual Life
Options Outstanding
Total
Number Shares
Exercisable
WeightedAverage
Exercise Price
During and the total intrinsic value the stock options exercised the difference
between the market price exercise and the price paid the employee exercise the options was million
million and million respectively The total cash received from the exercise these stock options was
million million and million for the years ended December and respectively
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The aggregate intrinsic value the outstanding stock options December was million
Options exercisable December and were million million and million
respectively The weighted average exercise prices options exercisable December and
were and respectively The weighted average remaining contractual life the exercisable
outstanding stock options December was years
December the Company had million stock options which are vested and expected vest
The intrinsic value weighted average price and remaining contractual life the vested and expected vest
stock options were million and years respectively December
December there were million total unrecognized compensation costs related
unvested stock option awards that are expected vest These costs are expected recognized over
weighted average period years
Restricted Stock
During the years ended December and the Company granted thousand thousand and
thousand shares restricted stock respectively The weighted average fair value per share the grant date
the restricted stock granted and was and respectively The
Company has recorded million million and million compensation expense each the years ended
December and respectively related the restricted stock grants December
the Company had thousand unvested shares restricted stock outstanding which have been fully expensed
Restricted Stock Units
The following table summarizes the unvested restricted stock unit award activity for the year ended
December thousands except for per share amounts
Shares
Weighted Average
Price
Unvested December
Granted
Vested
Forfeited
Unvested December
Restricted stock units are generally granted annually February and vest equal annual installments over
five year period The amount compensation costs recognized for the years ended December
and the restricted stock units expected vest were million million and million
respectively December there were million total unrecognized compensation costs related
the restricted stock unit awards that are expected vest These costs are expected recognized over
weighted average period years
Performance Stock Units
During year ended December the Company issued performance stock units which are equity
compensation awards with market vesting condition based the Company Total Shareholder Return
TSR relative the TSR the components the Health Care Index TSR the change value
stock price over time including the reinvestment dividends The vesting schedule ranges from
the target shares awarded
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
determining the fair value the performance stock units the Company makes variety assumptions
and estimates including volatility measures expected yields and expected terms The fair value each
performance stock unit grant was estimated the date grant using the Monte Carlo simulation model The
Company uses implied volatility its publicly traded options the basis for its estimate expected volatility
The Company believes that implied volatility the most appropriate indicator expected volatility because
generally reflective historical volatility and expectations how future volatility will differ from historical
volatility The expected life assumption for grants based the performance period the underlying
performance stock units The risk free interest rate the yield currently available Treasury zero coupon
issues with remaining term approximating the expected term used the input the Monte Carlo simulation
model The correlation coefficient used model the way which each company the Health Care
Index tends move relation each other during the performance period The relevant data used determine
the value the performance stock units granted during are follows
Performance Stock Units Issued and Significant Assumptions Used Estimate Fair Values
Performance stock units issued thousands
Risk free interest rate
Expected life years
Expected volatility
Average volatility peer companies
Correlation Coefficient
Expected dividends
The following table summarizes the unvested performance stock unit award activity for the year ended
December thousands except for per share amounts
Shares
Weighted Average
Fair Value
Unvested December
Granted
Unvested December
The amount compensation cost recognized for the year ended December the performance
stock units expected vest was less than million December there were million total
unrecognized compensation costs related the restricted stock unit awards that are expected vest These costs
are expected recognized over weighted average period years
Earnings Per Share
Basic and diluted EPS calculations are detailed follows thousands except per share data
Year Ended December
Weighted Average
Per
Net Income
Shares
Share
Numerator
Denominator
Amount
Net income per basic common share
Effect dilutive stock option restricted stock performance stock unit
and restricted stock unit securities
Net income per diluted common share
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
Year Ended December
Weighted Average
Per
Net Income
Shares
Share
Numerator
Denominator
Amount
Net income per basic common share
Effect dilutive stock option restricted stock and restricted stock unit
securities
Net income per diluted common share
Year Ended December
Net Income
Numerator
Weighted Average
Shares
Denominator
Per
Share
Amount
Net income per basic common share
Effect dilutive stock option restricted stock and restricted stock unit
securities
Net income per diluted common share
For the years ended December and the Company had million million and
million stock options that were antidilutive respectively due having higher exercise prices than the
Company average stock price during the period These securities were not included the computation
diluted EPS The effect dilutive securities was calculated using the treasury stock method
Accumulated Other Comprehensive Income
The components accumulated other comprehensive income are detailed follows thousands
Currency
Translation
Unrealized Gain
Loss
Retirement Plans
Unrealized Gain
Loss
Investments
Accumulated
Other
Comprehensive
Income Loss
Balance December
Other comprehensive loss net tax
Balance December
Retirement Plans
employees are eligible participate the Waters Employee Investment Plan defined contribution
plan immediately upon hire Employees may contribute eligible pay pre tax post tax basis
and the Company makes matching contributions for contributions eligible pay Employees
are vested employee and Company matching contributions For the years ended December
and the Company matching contributions amounted million million and million
respectively
The Company maintains two defined benefit plans the for which the pay credit accruals have been
frozen the Waters Retirement Plan and the Waters Retirement Restoration Plan collectively the Pension
Plans The Company also sponsors other employee benefit plans the including retiree healthcare plan
which provides reimbursement for medical expenses and contributory There are various employee benefit
plans outside the United States both defined benefit and defined contribution plans Certain non defined
benefit plans Non Pension Plans are included the disclosures below which are required under the
accounting standards for retirement benefits The Company made one time contributions totaling million
certain these Non Pension Plans during
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The Company contributed million million and million the years ended December
and respectively the non plans primarily defined contribution plans which are currently
outside the scope the required disclosures The eligibility and vesting non plans are consistent with
local laws and regulations
The net periodic pension cost made several components that reflect different aspects the
Company financial arrangements well the cost benefits earned employees These components are
determined using the projected unit credit actuarial cost method and are based certain actuarial assumptions
The Company accounting policy reflect the projected benefit obligation all benefit changes which the
Company committed the current valuation date use market related value assets determine pension
expense amortize increases prior service costs straight line basis over the expected future service
active participants the date such costs are first recognized and amortize cumulative actuarial gains and
losses excess the larger the market related value plan assets and the projected benefit
obligation over the expected future service active participants
Summary data for the Pension Plans Retiree Healthcare Plan and Non Pension Plans are
presented the following tables using the measurement dates December and respectively
The reconciliation the projected benefit obligations for the plans December and
follows thousands
Retiree
Healthcare
Plan
Pension
Plans
Non
Pension
Plans
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
Projected benefit obligation January
Service cost
Employee contributions
Interest cost
Actuarial losses gains
Benefits paid
Plan amendments
Plan settlements
Other plans
Currency impact
Projected benefit obligation
December
The accumulated benefit obligations for the plans December and are follows
thousands
Retiree
Healthcare
Plan
Pension
Plans
Accumulated benefit obligation
Not applicable
Non
Pension
Plans
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The reconciliation the fair value the plan assets December and follows
thousands
Pension
Plans
Retiree
Healthcare
Plan
Fair value plan assets January
Actual return plan assets
Company contributions
Employee contributions
Plan settlements
Benefits paid
Other plans
Currency impact
Fair value plan assets December
Non
Pension
Plans
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
The summary the funded status for the plans December and follows thousands
Retiree
Healthcare
Plan
Pension
Plans
Non
Pension
Plans
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
Projected benefit obligation
Fair value plan assets
Projected benefit obligation excess
fair value plan assets
The summary the amounts recognized the consolidated balance sheets for the plans December
and follows thousands
Retiree
Healthcare
Plan
Pension
Plans
Non
Pension
Plans
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
Long term assets
Current liabilities
Long term liabilities
Net amount recognized December
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The summary the components net periodic pension costs for the plans for the years ended
December and follows thousands
Retiree Non
Retiree Non
Retiree Non
Pension Healthcare Pension Pension Healthcare Pension Pension Healthcare Pension
Plans
Plan
Plans
Plans
Plan
Plans
Plans
Plan
Plans
Service cost
Interest cost
Expected return plan
assets
Settlement loss
Net amortization
Prior service credit
cost
Net actuarial loss
gain
Net periodic pension cost
benefit
The summary the changes amounts recognized other comprehensive loss for the plans for the years
ended December and follows thousands
Retiree Non
Retiree Non
Pension Healthcare Pension Pension Healthcare Pension
Plans
Plan
Plans
Plans
Plan
Plans
Prior service cost
credit
Net loss gain arising
during the year
Amortization
Prior service credit
cost
Net loss gain
Other Plans
Currency impact
Total recognized other
comprehensive loss
Pension
Plans
Retiree
Non
Healthcare Pension
Plan
Plans
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The summary the amounts included accumulated other comprehensive loss stockholders equity for
the plans December and follows thousands
Pension
Plans
Retiree
Healthcare
Plan
Net actuarial loss gain
Prior service credit
Total
Non
Pension
Plans
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
The summary the amounts included accumulated other comprehensive loss expected included
next year net periodic benefit cost for the plans December follows thousands
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
Net actuarial loss
Prior service credit
Total
The plans investment asset mix follows December and
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
Pension
Plans
Retiree
Healthcare
Plan
Non
Pension
Plans
Equity securities
Debt securities
Cash and cash equivalents
Insurance contracts and other
Total
The plans investment policies include the following asset allocation guidelines
Pension and Retiree
Healthcare Plans
Policy Target
Range
Equity securities
Debt securities
Cash and cash equivalents
Insurance contracts and other
Non
Pension Plans
Policy Target
The asset allocation policy for the Pension Plans and Retiree Healthcare Plan was developed
consideration the following long term investment objectives achieving return assets consistent with the
investment policy achieving portfolio returns which exceed the average return for similarly invested funds and
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
maximizing portfolio returns with least return above the one year constant maturity Treasury bond
yield over reasonable measurement periods and based reasonable market cycles
Within the equity portfolio the retirement plans investments are diversified among market
capitalization and investment strategy The Company targets allocation its retirement plans equity
portfolio invested financial markets outside the United States The Company does not invest its own
stock within the retirement plans assets
Plan assets are measured fair value using the following valuation techniques and inputs
Level
The fair value these types investments based market and observable sources from daily
quoted prices nationally recognized securities exchanges
Level
The fair value the money market funds held with financial institutions based the net asset
value the underlying treasury bill and commercial paper which are valued using third party
pricing services that utilize inputs such benchmark yields credit spreads and broker dealer
quotes determine the value
Level
These bank and insurance investment contracts are issued well known highly rated
companies The fair value disclosed represents the present value future cash flows under the
terms the respective contracts Significant assumptions used determine the fair value
these contracts include the amount and timing future cash flows and counterparty credit risk
There have been changes the above valuation techniques associated with determining the value the
plans assets during the years ended December and
the Company adopted new accounting guidance related the presentation certain investments
using the net asset value per share NAV practical expedient The accounting guidance exempts investments
using this practical expedient from categorization within the fair value hierarchy The Company applied the
adoption this standard retrospectively and removed certain investments from the fair value hierarchy both
periods Other than this change presentation the adoption this standard did not have impact the
Company consolidated financial statements
Investments valued NAV consist hedge funds the Pension Plans which are valued based
underlying investments equity securities companies where the hedge fund manager targeting
particular net long net short position the underlying stock The fair value these funds initially based
market and observable sources from daily quoted prices nationally recognized securities exchanges and then
adjustments are made the net asset value the hedge fund account for the effects any liquidation
redemption restrictions The redemption terms for the hedge funds are generally quarterly with day
notification period and there are redemption restrictions
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The fair value the Company retirement plan assets are follows December thousands
Total
December
Quoted Prices
Active
Markets for
Identical
Assets
Level
Significant
Other
Observable
Inputs
Level
Total Pension Plans
Retiree Healthcare Plan
Mutual funds
Total Retiree Healthcare Plan
Non Pension Plans
Cash equivalents
Mutual funds
Bank and insurance investment contracts
Total Non Pension Plans
Total fair value retirement plan assets
Investments valued NAV
Total retirement plan assets
Pension Plans
Mutual funds
Cash equivalents
Significant
Unobservable
Inputs
Level
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The fair value the Company retirement plan assets are follows December thousands
Total
December
Quoted
Prices
Active
Markets
for
Identical
Assets
Level
Significant
Other
Observable
Inputs
Level
Total Pension Plans
Retiree Healthcare Plan
Mutual funds
Cash equivalents
Total Retiree Healthcare Plan
Non Pension Plans
Cash equivalents
Mutual funds
Bank and insurance investment contracts
Pension Plans
Mutual funds
Common stocks
Cash equivalents
Total Non Pension Plans
Total fair value retirement plan assets
Investments valued NAV
Total retirement plan assets
Significant
Unobservable
Inputs
Level
The mutual fund balance the Pension Plans are invested the following categories the
common stock large cap companies the common stock international growth companies
and fixed income bonds issued companies and the government and its agencies
Primarily represents money market funds held with various financial institutions
The mutual fund balance the Retiree Healthcare Plan invested the following categories
the common stock large cap companies the common stock international growth
companies and fixed income bonds companies and government
Primarily represents deposit account funds held with various financial institutions
The mutual fund balance the Non Pension Plans primarily invested the following categories
international bonds the common stock international companies mortgages and real
estate and various other global investments
Amount represents bank and insurance guaranteed investment contracts
The mutual fund balance the Pension Plans are invested the following categories the
common stock large cap companies the common stock international growth companies
and fixed income bonds issued companies and the government and its agencies
Represents primarily amounts invested common stock technology healthcare financial energy and
consumer staples and discretionary companies
The mutual fund balance the Retiree Healthcare Plan invested the following categories
the common stock large cap companies the common stock international growth
companies and fixed income bonds companies and government
The mutual fund balance the Non Pension Plans invested the following categories
international bonds and the common stock international companies mortgages and real
estate and various other global investments
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The following table summarizes the changes fair value the Level retirement plan assets for the years
ended December and thousands
Insurance
Guaranteed
Investment
Contracts
Fair value assets December
Net purchases sales and appreciation depreciation
Fair value assets December
Net purchases sales and appreciation depreciation
Fair value assets December
The weighted average assumptions used determine the benefit obligation the consolidated balance
sheets December and are follows
Discount rate
Increases compensation levels
Non
Non
Non
Not applicable
The weighted average assumptions used determine the net periodic pension cost December
and are follows
Non
Non
Non
Discount rate
Return plan assets
Increases compensation levels
Not applicable
develop the expected long term rate return assets assumption the Company considered historical
returns and future expectations for returns for each asset class well the target asset allocation the pension
portfolio and historical expenses paid the plan one quarter percentage point increase the assumed longterm rate return assets would decrease the Company net periodic benefit cost for the Waters Retirement
Plan less than million one quarter percentage point increase the discount rate would decrease the
Company net periodic benefit cost for the Waters Retirement Plan less than million
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
During fiscal year the Company expects contribute total approximately million
million the Company defined benefit plans Estimated future benefit payments from the plans
December are follows thousands
Pension and
Retiree Healthcare
Plans
Non
Pension
Plans
Total
Business Segment Information
The accounting standards for segment reporting establish standards for reporting information about operating
segments annual financial statements and require selected information for those segments presented
interim financial reports public business enterprises They also establish standards for related disclosures about
products and services geographic areas and major customers The Company business activities for which
discrete financial information available are regularly reviewed and evaluated the chief operating decision
maker result this evaluation the Company determined that has two operating segments Waters and
The Waters operating segment primarily the business designing manufacturing distributing and
servicing and instruments columns and other chemistry consumables that can integrated and used
along with other analytical instruments The operating segment primarily the business designing
manufacturing distributing and servicing thermal analysis rheometry and calorimetry instruments The
Company two operating segments have similar economic characteristics product processes products and
services types and classes customers methods distribution and regulatory environments Because these
similarities the two segments have been aggregated into one reporting segment for financial statement purposes
Please refer the consolidated financial statements for financial information regarding the one reportable
segment the Company
Net sales for the Company products and services are follows for the years ended December
and thousands
Total product sales
Service net sales
Waters service
service
Total service sales
Total net sales
Product net sales
Waters instrument systems
Chemistry
instrument systems
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
Geographic sales information presented below for the years ended December and
thousands
Total Asia
Other
Total net sales
Net Sales
United States
Europe
Asia
China
Japan
Asia Other
The Other category includes Canada Latin America and Puerto Rico Net sales are attributable
geographic areas based the region destination None the Company individual customers accounts for
more than annual Company sales
Long lived assets information December and presented below thousands
Long lived assets
United States
Europe
Asia
Other
Total long lived assets
The Other category includes Canada Latin America and Puerto Rico Long lived assets exclude goodwill
other intangible assets and other assets
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
Unaudited Quarterly Results
The Company unaudited quarterly results are summarized below thousands except per share data
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Total
Net sales
Costs and operating expenses
Cost sales
Selling and administrative expenses
Research and development expenses
Purchased intangibles amortization
Litigation provisions
Total costs and operating expenses
Operating income
Interest expense
Interest income
Income from operations before income taxes
Provision for income tax expense
Net income
Net income per basic common share
Weighted average number basic common
shares
Net income per diluted common share
Weighted average number diluted common
shares and equivalents
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Total
Operating income
Interest expense
Interest income
Income from operations before income taxes
Provision for income tax expense
Net income
Net income per basic common share
Weighted average number basic common
shares
Net income per diluted common share
Weighted average number diluted common
shares and equivalents
Net sales
Costs and operating expenses
Cost sales
Selling and administrative expenses
Research and development expenses
Purchased intangibles amortization
Litigation provisions
Acquired process research and development
Total costs and operating expenses
NOTES CONSOLIDATED FINANCIAL STATEMENTS Continued
The Company typically experiences increase sales the fourth quarter result purchasing habits
for capital goods customers that tend exhaust their spending budgets calendar year end Selling and
administrative expenses are typically higher the second and third quarters over the first quarter each year
the Company annual payroll merit increases take effect Selling and administrative expenses will vary the
fourth quarter relation performance the quarter and for the year
the first quarter the Company recorded million stock compensation expense selling and
administrative expenses related the modification certain stock awards upon the retirement senior
executives the fourth quarters and the company recorded million provisions related
litigation see Note the fourth quarter the Company recorded million charge related
acquired process research and development see Note
Item
Changes and Disagreements with Accountants Accounting and Financial Disclosure
None
Item Controls and Procedures
Evaluation Disclosure Controls and Procedures
The Company chief executive officer and chief financial officer principal executive and principal financial
officer with the participation management evaluated the effectiveness the Company disclosure controls
and procedures defined Rules and under the Exchange Act the end the period
covered this annual report Form Based this evaluation the Company chief executive officer and
chief financial officer concluded that the Company disclosure controls and procedures were effective
December ensure that information required disclosed the Company including its
consolidated subsidiaries the reports that files submits under the Exchange Act accumulated and
communicated the Company management including its chief executive officer and chief financial officer
allow timely decisions regarding the required disclosure and provide reasonable assurance that information
required disclosed the Company the reports that files submits under the Exchange Act
recorded processed summarized and reported within the time periods specified the SEC rules and forms
Management Annual Report Internal Control Over Financial Reporting
See Management Report Internal Control Over Financial Reporting Item page this Form
Report the Independent Registered Public Accounting Firm
See the report PricewaterhouseCoopers LLP Item page this Form
Changes Internal Controls Over Financial Reporting
change was identified the Company internal control over financial reporting defined
Rules and under the Exchange Act during the quarter ended December that has
materially affected reasonably likely materially affect the Company internal control over financial
reporting
Item
Other Information
None
PART III
Item Directors Executive Officers and Corporate Governance
Information regarding the Company directors contained the definitive proxy statement for the
Annual Meeting Stockholders under the headings Election Directors Directors Meetings and Board
Committees Corporate Governance Report the Audit Committee the Board Directors and
Compensation Directors and Executive Officers Information regarding compliance with Section
the Exchange Act contained the Company definitive proxy statement for the Annual Meeting
Stockholders under the heading Section Beneficial Ownership Reporting Compliance Information
regarding the Company Audit Committee and Audit Committee Financial Expert contained the definitive
proxy statement for the Annual Meeting Stockholders under the headings Report the Audit
Committee the Board Directors and Directors Meetings and Board Committees Such information
incorporated herein reference Information regarding the Company executive officers contained Part
this Form
The Company has adopted Code Business Conduct and Ethics the Code that applies all the
Company employees including its executive officers and directors and that compliance with Item
Regulation The Code has been distributed all employees the Company addition the Code
available the Company website waters under the caption Governance The Company intends
satisfy the disclosure requirement regarding any amendment waiver provision the Code
applicable any executive officer director posting such information its website The Company shall
also provide any person without charge upon request copy the Code Any such request must made
writing the Secretary the Company Waters Corporation Maple Street Milford
The Company corporate governance guidelines and the charters the audit committee compensation
committee and nominating and corporate governance committee the Board Directors are available the
Company website waters under the caption Governance The Company shall provide any
person without charge upon request copy any the foregoing materials Any such request must made
writing the Secretary the Company Waters Corporation Maple Street Milford
The Company has not made any material changes the procedures which security holders may
recommend nominees the Company Board Directors
Item Executive Compensation
This information contained the Company definitive proxy statement for the Annual Meeting
Stockholders under the headings Compensation Directors and Executive Officers Compensation
Committee Interlocks and Insider Participation and Compensation Committee Report Such information
incorporated herein reference
Item Security Ownership Certain Beneficial Owners and Management and Related Stockholder
Matters
Except for the Equity Compensation Plan information set forth below this information contained the
Company definitive proxy statement for the Annual Meeting Stockholders under the heading Security
Ownership Certain Beneficial Owners and Management Such information incorporated herein
reference
Equity Compensation Plan Information
The following table provides information December about the Company common stock that may
issued upon the exercise options warrants and rights under its existing equity compensation plans
thousands
Number Securities
Issued Upon Exercise
Outstanding Options
Warrants and Rights
Weighted Average
Exercise Price
Outstanding Options
Warrants and Rights
Number Securities
Remaining Available for
Future Issuance Under
Equity Compensation
Plans excluding
securities reflected
column
Equity compensation plans approved
security holders
Equity compensation plans not approved
security holders
Total
See Note Stock Based Compensation the Notes Consolidated Financial Statements for
description the material features the Company equity compensation plans
Item Certain Relationships and Related Transactions and Director Independence
This information contained the Company definitive proxy statement for the Annual Meeting
Stockholders under the headings Directors Meetings and Board Committees Corporate Governance and
Compensation Directors and Executive Officers Such information incorporated herein reference
Item Principal Accountant Fees and Services
This information contained the Company definitive proxy statement for the Annual Meeting
Stockholders under the headings Ratification Selection Independent Registered Public Accounting Firm
and Report the Audit Committee the Board Directors Such information incorporated herein
reference
PART
Item Exhibits Financial Statement Schedules
Documents filed part this report
Financial Statements
The consolidated financial statements the Company and its subsidiaries are filed part this
Form and are set forth pages The report PricewaterhouseCoopers LLP
independent registered public accounting firm dated February set forth page
this Form
Financial Statement Schedule
See below
Exhibits
Exhibit
Number
Description Document
Second Amended and Restated Certificate Incorporation Waters Corporation
Certificate Amendment Second Amended and Restated Certificate Incorporation Waters
Corporation dated May
Certificate Amendment Second Amended and Restated Certificate Incorporation Waters
Corporation dated July
Certificate Amendment Second Amended and Restated Certificate Incorporation Waters
Corporation dated May
Amended and Restated Bylaws Waters Corporation dated October
Waters Corporation Retirement Plan
Waters Corporation Equity Incentive Plan
First Amendment the Waters Corporation Equity Incentive Plan
Form Director Stock Option Agreement under the Waters Corporation Equity Incentive Plan
amended
Form Director Restricted Stock Agreement under the Waters Corporation Equity Incentive
Plan amended
Form Executive Officer Stock Option Agreement under the Waters Corporation Equity
Incentive Plan amended
Second Amendment the Waters Corporation Equity Incentive Plan
Third Amendment the Waters Corporation Equity Incentive Plan
Amended and Restated Waters Restoration Plan effective January
Change Control Severance Agreement dated February between Waters
Corporation and Mark Beaudouin
Change Control Severance Agreement dated February between Waters
Corporation and Arthur Caputo
Change Control Severance Agreement dated February between Waters
Corporation and Elizabeth Rae
Exhibit
Number
Description Document
Change Control Severance Agreement dated February between Waters
Corporation and Eugene Cassis
Amended and Restated Waters Retirement Restoration Plan effective January
Amended and Restated Waters Corporation Non Employee Director Deferred Compensation
Plan Effective January
Waters Corporation Management Incentive Plan
Waters Corporation Employee Stock Purchase Plan
Note Purchase Agreement dated February between Waters Corporation and the
purchases named therein
First Amendment the Note Purchase Agreement dated February
Note Purchase Agreement dated March between Waters Corporation and the purchases
named therein
Waters Corporation Equity Incentive Plan
Form Waters Stock Option Agreement Executive Officers
Form Waters Stock Option Agreement Directors
Form Waters Restricted Stock Agreement Directors
Credit Agreement dated June among Waters Corporation JPMorgan Chase Bank
Morgan Europe Limited and other Lenders party thereto
Form Waters Restricted Stock Unit Agreement for Executive Officers Five Year
Vesting
Form Waters Restricted Stock Unit Agreement for Executive Officers One Year
Vesting
Note Purchase Agreement dated June between Waters Corporation and the purchases
named therein
Change Control Severance Agreement dated April between Waters Corporation and
Michael Silveira
Credit Agreement dated April among Waters Corporation JPMorgan Chase Bank
Morgan Europe Limited and other Lenders party thereto
President and Chief Executive Employment Agreement
Change Control Severance Agreement dated September between Waters
Corporation and Christopher Connell
Note Purchase Agreement dated May between Waters Corporation and the
purchasers named therein
Form Waters Performance Stock Unit Award Agreement
Senior Vice President and Chief Financial Officer Employment Agreement
Change Control Severance Agreement dated January between Waters Corporation
and Sherry Buck
Exhibit
Number
Description Document
Subsidiaries Waters Corporation
Consent PricewaterhouseCoopers LLP independent registered public accounting firm
Chief Executive Officer Certification Pursuant Section the Sarbanes Oxley Act
Chief Financial Officer Certification Pursuant Section the Sarbanes Oxley Act
Chief Executive Officer Certification Pursuant Section Adopted Pursuant
Section the Sarbanes Oxley Act
Chief Financial Officer Certification Pursuant Section Adopted Pursuant
Section the Sarbanes Oxley Act
The following materials from Waters Corporation Annual Report Form for the year ended
December formatted XBRL Extensible Business Reporting Language the
Consolidated Balance Sheets the Consolidated Statements Operations iii the Consolidated
Statements Comprehensive Income the Consolidated Statements Cash Flows the
Consolidated Statements Stockholders Equity and Notes Consolidated Financial
Statements
Incorporated reference the Registrant Report Form dated March File
Incorporated reference the Registrant Registration Statement Form File
Incorporated reference the Registrant Report Form dated August File
Incorporated reference the Registrant Report Form dated August File
Incorporated reference the Registrant Report Form dated March File
Incorporated reference the Registrant Report Form dated November File
Incorporated reference the Registrant Report Form dated March File
Incorporated reference the Registrant Report Form dated November File
Incorporated reference the Registrant Report Form dated August File
Incorporated reference the Registrant Report Form dated March File
Incorporated reference the Registrant Report Form dated November File
Incorporated reference the Registrant Report Form dated February File
Incorporated reference the Registrant Report Form dated February File
Incorporated reference the Registrant Report Form dated July File
Incorporated reference the Registrant Report Form dated February File
Incorporated reference the Registrant Report Form dated May File
Incorporated reference the Registrant Report Form dated September File
Incorporated reference the Registrant Report Form dated December File
Incorporated reference the Registrant Report Form dated August File
Incorporated reference the Registrant Report Form dated November File
Incorporated reference the Registrant Report Form dated December File
Incorporated reference the Registrant Report Form dated August File
Incorporated reference the Registrant Report Form dated February File
Incorporated reference the Registrant Report Form dated May File
Incorporated reference the Registrant Report Form dated August File
Incorporated reference the Registrant Report Form dated August File
Incorporated reference the Registrant Report Form dated December File
Management contract compensatory plan required filed Exhibit this Form
This exhibit shall not deemed filed for purposes Section the Exchange Act otherwise
subject the liability that section nor shall deemed incorporated reference into any filing under
the Securities Act amended the Exchange Act whether made before after the date hereof
and irrespective any general incorporation language any filing except the extent the Company
specifically incorporates reference
See Item above
Financial Statement Schedule
The following additional financial statement schedule should considered conjunction with the
consolidated financial statements All other schedules have been omitted because the required information
either not applicable not sufficiently material require submission the schedule
WATERS CORPORATION AND SUBSIDIARIES
SCHEDULE VALUATION AND QUALIFYING ACCOUNTS
For each the three years the period ended December
Valuation allowance for deferred tax assets
Balance
Beginning
Period
Charged
Provision
for Income
Taxes
Other
Balance
End
Period
These amounts have been recorded part the income statement provision for income taxes The income
statement effects these amounts have largely been offset amounts related changes other deferred
tax balance sheet accounts
The change the valuation allowance during the year ended December primarily due the
effect foreign currency translation valuation allowance related net operating loss carryforward
and the release valuation allowance related foreign tax credit carryforward due expiration The
change the valuation allowance during the year ended December primarily due the effect
foreign currency translation valuation allowance related net operating loss carryforward
Item Form Summary
The optional summary Item has not been included this Form
SIGNATURES
Pursuant the requirements Section the Securities Exchange Act the registrant
has duly caused this report signed its behalf the undersigned thereunto duly authorized
WATERS CORPORATION
SHERRY BUCK
Sherry Buck
Senior Vice President and
Chief Financial Officer
Date February
Pursuant the requirements the Securities Exchange Act this report has been signed the
following persons behalf the registrant and the capacities indicated February
CHRISTOPHER CONNELL
Christopher Connell
SHERRY BUCK
Sherry Buck
Senior Vice President and Chief Financial Officer
principal financial officer
principal accounting officer
DOUGLAS BERTHIAUME
Douglas Berthiaume
Chairman the Board Directors
President and Chief Executive Officer
principal executive officer
JOSHUA BEKENSTEIN
Joshua Bekenstein
Director
MICHAEL BERENDT
Michael Berendt
Director
EDWARD CONARD
Edward Conard
Director
LAURIE GLIMCHER
Laurie Glimcher
Director
CHRISTOPHER KUEBLER
Christopher Kuebler
Director
WILLIAM MILLER
William Miller
Director
JOANN REED
JoAnn Reed
Director
THOMAS SALICE
Thomas Salice
Director
Directors
Executive Officers
Douglas Berthiaume
Chairman the Board
Waters Corporation
Christopher Connell
President and Chief
Executive Officer
Christopher Connell
President and
Chief Executive Officer
Waters Corporation
Mark Beaudouin
Senior Vice President
General Counsel and Secretary
Joshua Bekenstein
Managing Director
Bain Capital LLC
Michael Berendt
Life Sciences Industry Consultant
and Investor
Edward Conard
Independent Director and Investor
Laurie Glimcher
President and CEO
Dana Farber Cancer Institute
Principal Investigator and Director
Dana Farber Harvard Cancer Center
Richard and Susan Smith Professor
Medicine Harvard Medical School
Christopher Kuebler
Retired Chairman and Chief
Executive Officer Covance Inc
William Miller
Independent Director and Investor
JoAnn Reed
Health Care Services Consultant
Thomas Salice
Managing Member
SFW Capital Partners LLC
Sherry Buck
Senior Vice President and
Chief Financial Officer
Eugene Cassis
Senior Vice President
Michael Harrington
Senior Vice President
Global Markets
Terrence Kelly
Senior Vice President and President
Instruments
Rohit Khanna
Senior Vice President
Applied Technology
Ian King
Senior Vice President
Instrument Technology
Elizabeth Rae
Senior Vice President
Global Human Resources
David Terricciano
Senior Vice President
Global Operations
Transfer Agent and Registrar
Shareholder correspondence
should mailed
Computershare
Box
College Station
Overnight correspondence
should mailed
Computershare
Quality Circle Suite
College Station
Shareholder website
computershare
investor
Shareholder online inquiries
computershare
investor Contact
Independent Registered
Public Accounting Firm
PricewaterhouseCoopers LLP
Seaport Boulevard
Boston
Phone
Attorneys
Ropes Gray LLP
Prudential Tower
Boylston Street
Boston
Phone
Stockholders Meeting
Date Tuesday May
Location
Waters Corporation
Maple Street
Milford
Directions Call
Ext
waters directionsMilford
Stocklist Symbol
NYSE WAT
Investor Relations
John Lynch
Vice President Treasurer and
Investor Relations
Phone
john_lynch waters
Form
copy the Company filed
with the Securities and Exchange
Commission available without
charge upon written request
Waters Corporation
Maple Street
Milford
Offices
Corporate Headquarters
Waters Corporation
Maple Street
Milford
Phone
Toll Free
Fax
Email info waters
URL waters
Waters Annual Report
Waters The Science What Possible ACQUITY Alliance Empower QDa UPLC and
Xevo are registered trademarks Waters Corporation ACQUITY Arc and Discovery
Series are trademarks Waters Corporation All other trademarks are the property
their respective owners
Waters Corporation Printed the March RRD
Waters Corporation
Maple Street
Milford
waters
